<html lang="en" class="pb-page js" data-request-id="94d68a6c257f6224-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d68a6c257f6224-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/c3y5PAW4-IFhvey4-fV6jqM09XsOiHlmqLD9wfX0n_Z4bKBOXbp760emP0m36jYBQUJDdhAho6gDrVxenk5C9w=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d68a6c257f6224-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.23839305462254368"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Treatments in Oncology|Leukemia/Lymphoma">
<meta name="Specialties" content="Hematology/Oncology"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2028631","title":"Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","category":"Research","type":"Original Article","topics":"Treatments in Oncology|Leukemia/Lymphoma","specialties":"Hematology/Oncology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-07-01T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Treatments in Oncology|Leukemia/Lymphoma\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Hematology/Oncology\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2028631","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Research Summary","title":"Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","doi":"10.1056/NEJMdo006080","issueDate":"2021-07-01T00:00Z","age":"6Months-1990","isFree":"n","topics":"Treatments in Oncology|Leukemia/Lymphoma","viewType":"Full","specialties":"Hematology/Oncology"},{"type":"Quick Take","title":"A CD38-Targeting Antibody for AL Amyloidosis","doi":"10.1056/NEJMdo006079","issueDate":"2021-07-01T00:00Z","age":"6Months-1990","isFree":"n","topics":"Treatments in Oncology|Leukemia/Lymphoma","viewType":"Full","specialties":"Hematology/Oncology"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d68a6c257f6224-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis"><meta name="dc.Creator" content="Efstathios Kastritis"><meta name="dc.Creator" content="Giovanni Palladini"><meta name="dc.Creator" content="Monique C. Minnema"><meta name="dc.Creator" content="Ashutosh D. Wechalekar"><meta name="dc.Creator" content="Arnaud Jaccard"><meta name="dc.Creator" content="Hans C. Lee"><meta name="dc.Creator" content="Vaishali Sanchorawala"><meta name="dc.Creator" content="Simon Gibbs"><meta name="dc.Creator" content="Peter Mollee"><meta name="dc.Creator" content="Christopher P. Venner"><meta name="dc.Creator" content="Jin Lu"><meta name="dc.Creator" content="Stefan Schönland"><meta name="dc.Creator" content="Moshe E. Gatt"><meta name="dc.Creator" content="Kenshi Suzuki"><meta name="dc.Creator" content="Kihyun Kim"><meta name="dc.Creator" content="M. Teresa Cibeira"><meta name="dc.Creator" content="Meral Beksac"><meta name="dc.Creator" content="Edward Libby"><meta name="dc.Creator" content="Jason Valent"><meta name="dc.Creator" content="Vania Hungria"><meta name="dc.Creator" content="Sandy W. Wong"><meta name="dc.Creator" content="Michael Rosenzweig"><meta name="dc.Creator" content="Naresh Bumma"><meta name="dc.Creator" content="Antoine Huart"><meta name="dc.Creator" content="Meletios A. Dimopoulos"><meta name="dc.Creator" content="Divaya Bhutani"><meta name="dc.Creator" content="Adam J. Waxman"><meta name="dc.Creator" content="Stacey A. Goodman"><meta name="dc.Creator" content="Jeffrey A. Zonder"><meta name="dc.Creator" content="Selay Lam"><meta name="dc.Creator" content="Kevin Song"><meta name="dc.Creator" content="Timon Hansen"><meta name="dc.Creator" content="Salomon Manier"><meta name="dc.Creator" content="Wilfried Roeloffzen"><meta name="dc.Creator" content="Krzysztof Jamroziak"><meta name="dc.Creator" content="Fiona Kwok"><meta name="dc.Creator" content="Chihiro Shimazaki"><meta name="dc.Creator" content="Jin-Seok Kim"><meta name="dc.Creator" content="Edvan Crusoe"><meta name="dc.Creator" content="Tahamtan Ahmadi"><meta name="dc.Creator" content="NamPhuong Tran"><meta name="dc.Creator" content="Xiang Qin"><meta name="dc.Creator" content="Sandra Y. Vasey"><meta name="dc.Creator" content="Brenda Tromp"><meta name="dc.Creator" content="Jordan M. Schecter"><meta name="dc.Creator" content="Brendan M. Weiss"><meta name="dc.Creator" content="Sen H. Zhuang"><meta name="dc.Creator" content="Jessica Vermeulen"><meta name="dc.Creator" content="Giampaolo Merlini"><meta name="dc.Creator" content="Raymond L. Comenzo"><meta name="dc.Description" content="Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting ant..."><meta name="Description" content="Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting ant..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-07-01"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2028631"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202107013850110"><meta name="dc.Language" content="EN"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2021 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2028631">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2028631">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2028631">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis | NEJM">
        <meta property="og:title" content="Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2028631">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/6cb2c449-c7e6-4786-a365-d1cd1f17b89b/nejmoa2028631_f0.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/6cb2c449-c7e6-4786-a365-d1cd1f17b89b/nejmoa2028631_f0.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition
of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab,
a human CD38-targeting ant...">
        <meta name="twitter:description" content="Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition
of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab,
a human CD38-targeting ant...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3416">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2028631">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2028631">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:MMS NextGen Website Group;article:article:doi\:10.1056/NEJMoa2028631;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms;issue:issue:doi\:10.1056/nejm_2021.385.issue-1">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2028631" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2028631" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2028631" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2028631" class="inputDoi"><input type="hidden" value="E. Kastritis and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;385:46-58" class="inputCitation"><input type="hidden" value="06-30-2021" class="inputEPubDate"><input type="hidden" value="July 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d68a6c257f6224-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Efstathios</span> <span property="familyName">Kastritis</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Giovanni</span> <span property="familyName">Palladini</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Monique C.</span> <span property="familyName">Minnema</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ashutosh D.</span> <span property="familyName">Wechalekar</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Arnaud</span> <span property="familyName">Jaccard</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Hans C.</span> <span property="familyName">Lee</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Vaishali</span> <span property="familyName">Sanchorawala</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+43</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Simon</span> <span property="familyName">Gibbs</span>, <span property="honorificSuffix">M.B., B.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Peter</span> <span property="familyName">Mollee</span>, <span property="honorificSuffix">M.B., B.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Christopher P.</span> <span property="familyName">Venner</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jin</span> <span property="familyName">Lu</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Stefan</span> <span property="familyName">Schönland</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Moshe E.</span> <span property="familyName">Gatt</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kenshi</span> <span property="familyName">Suzuki</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kihyun</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">M. Teresa</span> <span property="familyName">Cibeira</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Meral</span> <span property="familyName">Beksac</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Edward</span> <span property="familyName">Libby</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jason</span> <span property="familyName">Valent</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Vania</span> <span property="familyName">Hungria</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sandy W.</span> <span property="familyName">Wong</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Michael</span> <span property="familyName">Rosenzweig</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Naresh</span> <span property="familyName">Bumma</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Antoine</span> <span property="familyName">Huart</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Meletios A.</span> <span property="familyName">Dimopoulos</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Divaya</span> <span property="familyName">Bhutani</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Adam J.</span> <span property="familyName">Waxman</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Stacey A.</span> <span property="familyName">Goodman</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jeffrey A.</span> <span property="familyName">Zonder</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Selay</span> <span property="familyName">Lam</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kevin</span> <span property="familyName">Song</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Timon</span> <span property="familyName">Hansen</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Salomon</span> <span property="familyName">Manier</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Wilfried</span> <span property="familyName">Roeloffzen</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Krzysztof</span> <span property="familyName">Jamroziak</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Fiona</span> <span property="familyName">Kwok</span>, <span property="honorificSuffix">M.B., B.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Chihiro</span> <span property="familyName">Shimazaki</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jin-Seok</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Edvan</span> <span property="familyName">Crusoe</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Tahamtan</span> <span property="familyName">Ahmadi</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">NamPhuong</span> <span property="familyName">Tran</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Xiang</span> <span property="familyName">Qin</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sandra Y.</span> <span property="familyName">Vasey</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Brenda</span> <span property="familyName">Tromp</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jordan M.</span> <span property="familyName">Schecter</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Brendan M.</span> <span property="familyName">Weiss</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sen H.</span> <span property="familyName">Zhuang</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jessica</span> <span property="familyName">Vermeulen</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Giampaolo</span> <span property="familyName">Merlini</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Raymond L.</span> <span property="familyName">Comenzo</span>, <span property="honorificSuffix">M.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the ANDROMEDA Trial Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-43</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">June 30, 2021</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">385</span></span>:<span property="pageStart">46</span>-<span property="pageEnd">58</span></div><div class="doi">DOI: 10.1056/NEJMoa2028631</div><div class="core-enumeration"><a href="/toc/nejm/385/1"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">385</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">1</span></span></a></div><div><a href="#tab-information">Copyright © 2021</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DEfstathios%2BKastritis%252C%2BGiovanni%2BPalladini%252C%2BMonique%2BC.%2BMinnema%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D1%26contentID%3D10.1056%252FNEJMoa2028631%26title%3DDaratumumab-Based%2BTreatment%2Bfor%2BImmunoglobulin%2BLight-Chain%2BAmyloidosis%26publicationDate%3D07%252F01%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2028631" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DEfstathios%2BKastritis%252C%2BGiovanni%2BPalladini%252C%2BMonique%2BC.%2BMinnema%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D1%26contentID%3D10.1056%252FNEJMoa2028631%26title%3DDaratumumab-Based%2BTreatment%2Bfor%2BImmunoglobulin%2BLight-Chain%2BAmyloidosis%26publicationDate%3D07%252F01%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/925f790b-dcf4-4ef2-9c92-7bb5078c807f/nejmoa2028631.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2028631.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2028631" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2028631" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2028631.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We randomly assigned patients with newly diagnosed AL amyloidosis to receive six cycles of bortezomib, cyclophosphamide, and dexamethasone either alone (control group) or with subcutaneous daratumumab followed by single-agent daratumumab every 4 weeks for up to 24 cycles (daratumumab group). The primary end point was a hematologic complete response.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><!-- There is no content. --><nav><a href="#f0" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028631_f0.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f0" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028631_f0.jpg"><img src="/cms/10.1056/NEJMoa2028631/asset/6cb2c449-c7e6-4786-a365-d1cd1f17b89b/assets/images/large/nejmoa2028631_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 388 patients underwent randomization. The median follow-up was 11.4 months. The percentage of patients who had a hematologic complete response was significantly higher in the daratumumab group than in the control group (53.3% vs. 18.1%) (relative risk ratio, 2.9; 95% confidence interval [CI], 2.1 to 4.1; P&lt;0.001). Survival free from major organ deterioration or hematologic progression favored the daratumumab group (hazard ratio for major organ deterioration, hematologic progression, or death, 0.58; 95% CI, 0.36 to 0.93; P=0.02). At 6 months, more cardiac and renal responses occurred in the daratumumab group than in the control group (41.5% vs. 22.2% and 53.0% vs. 23.9%, respectively). The four most common grade 3 or 4 adverse events were lymphopenia (13.0% in the daratumumab group and 10.1% in the control group), pneumonia (7.8% and 4.3%, respectively), cardiac failure (6.2% and 4.8%), and diarrhea (5.7% and 3.7%). Systemic administration-related reactions to daratumumab occurred in 7.3% of the patients. A total of 56 patients died (27 in the daratumumab group and 29 in the control group), most due to amyloidosis-related cardiomyopathy.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Among patients with newly diagnosed AL amyloidosis, the addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone was associated with higher frequencies of hematologic complete response and survival free from major organ deterioration or hematologic progression. (Funded by Janssen Research and Development; ANDROMEDA ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03201965" target="_blank">NCT03201965</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo006079/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/94a99511-7d48-4201-b4a2-7abb1a07d5d8/media/NEJMdo006079_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo006079/full/" class="ng-do-media_item-title-link">A CD38-Targeting Antibody for AL Amyloidosis</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 0s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph"><a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><a id="exam-tint-one-c"></a><a id="exam-tint-one-d"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">Immunoglobulin light-chain (AL) amyloidosis is a lethal form of systemic amyloidosis arising from clonal expansion of CD38+ plasma cells that produce misfolded immunoglobulin light chains, which form amyloid fibrils that are deposited in tissues. This process results in organ damage, most frequently to the heart and kidneys.</span><sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1-1" href-manipulated="true" aria-label="Reference 1">1</a></sup> Diagnosis is often delayed, and the prognosis is poor, owing to advanced multiorgan involvement that leads to progressive disability and death.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2 r3" id="body-ref-r3-1" href-manipulated="true">1-3</a></sup> Standard treatment involves the use of multiple myeloma–derived therapies that target plasma cells; a combination of bortezomib, cyclophosphamide, and dexamethasone is the most commonly used regimen.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4 r5" id="body-ref-r5-1" href-manipulated="true">3-5</a></sup> Rapid and deep hematologic responses are critical; however, despite improvements with bortezomib-containing therapy, rates of hematologic complete response remain suboptimal, early mortality is high, outcomes vary depending on the extent and severity of organ involvement, and treatment-related toxic effects are frequently observed.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6" id="body-ref-r6" href-manipulated="true" aria-label="Reference 6">6</a></sup> Until recently, no approved treatment options were available.</div><div role="paragraph"><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">Daratumumab is a human IgG-κ monoclonal antibody that targets CD38, a glycoprotein uniformly expressed on human plasma cells.</span> Daratumumab has a direct antitumor<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8 r9 r10" id="body-ref-r10" href-manipulated="true">7-10</a></sup> and immunomodulatory mechanism,<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11 r12 r13" id="body-ref-r13" href-manipulated="true">11-13</a></sup> with demonstrated efficacy as monotherapy or in combination with standard-of-care regimens for multiple myeloma.<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14-1" href-manipulated="true" aria-label="Reference 14">14</a></sup> In patients with relapsed or refractory AL amyloidosis, daratumumab has shown promising efficacy in terms of hematologic responses and improvement in organ function.<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15 r16 r17 r18 r19 r20 r21" id="body-ref-r21" href-manipulated="true">15-21</a></sup> In the phase 3 ANDROMEDA trial, we evaluated the safety and efficacy of subcutaneous daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed AL amyloidosis. A safety run-in phase showed that the combination had an acceptable side-effect profile.<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22" href-manipulated="true" aria-label="Reference 22">22</a></sup> Here we report the primary results from the randomized portion of the trial.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Oversight</h3><div role="paragraph">This phase 3, open-label, randomized, active-controlled trial enrolled patients between May 3, 2018, and August 15, 2019, at 109 sites in 22 countries across North and South America, Europe, the Middle East, and the Asia–Pacific region. The trial was conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice guidelines. The trial <a href="#ap1">protocol</a> (available with the full text of this article at NEJM.org) was approved by an institutional review board or independent ethics committee at each trial site, and all the patients provided written informed consent. Efficacy data were adjudicated by an independent review committee whose members were unaware of the trial-group assignments, and an independent data monitoring committee assessed the results of the interim analysis.</div><div role="paragraph">The trial sponsor (Janssen Research and Development) designed the trial and compiled and maintained the data. Authors were given access to the data and were not restricted by confidentiality agreements. Professional medical writers that were funded by the sponsor prepared the manuscript. All the authors reviewed, revised, and approved the manuscript for submission. All the authors vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol.</div></section><section id="sec-1-2"><h3>Patients</h3><div role="paragraph">Eligible patients were at least 18 years of age with a histopathologic diagnosis of systemic AL amyloidosis (affecting one or more organs) and measurable hematologic disease. Patients were excluded if they had received previous therapy for AL amyloidosis, had symptomatic multiple myeloma according to International Myeloma Working Group criteria,<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23" href-manipulated="true" aria-label="Reference 23">23</a></sup> had an Eastern Cooperative Oncology Group performance-status score of more than 2 (on a 5-point scale in which higher numbers indicate greater disability), had an estimated glomerular filtration rate of less than 20 ml per minute per 1.73 m<sup>2</sup> of body-surface area, or had evidence of a severe cardiovascular condition including an N-terminal pro–B-type natriuretic peptide level of more than 8500 ng per liter, a systolic blood pressure of less than 90 mm Hg, or a New York Heart Association classification of stage IIIB or IV at screening. Full eligibility criteria are provided in the trial protocol.</div></section><section id="sec-1-3"><h3>Randomization and Trial Treatments</h3><div role="paragraph">With the use of an interactive Web-response system, patients were randomly assigned in a 1:1 ratio to receive bortezomib, cyclophosphamide, and dexamethasone alone (control group) or the same therapy with subcutaneous daratumumab (daratumumab group) (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org). Randomization was stratified according to cardiac stage (I, II, or IIIA on the basis of the European modification of the Mayo Clinic Cardiac Staging System),<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3-3" href-manipulated="true" aria-label="Reference 3">3</a></sup> availability of transplantation in the local country (countries that do or do not typically offer transplantation for patients with AL amyloidosis), and renal function (creatinine clearance, ≥60 ml per minute or &lt;60 ml per minute). Treatment assignments were not blinded.</div><div role="paragraph">All the patients received subcutaneous bortezomib at a dose of 1.3 mg per square meter of body-surface area, cyclophosphamide at a dose of 300 mg per square meter orally or intravenously (500 mg maximum weekly dose), and dexamethasone at a dose of 40 mg orally or intravenously once weekly for six cycles of 28 days each. For patients who were older than 70 years of age, were underweight (body-mass index [the weight in kilograms divided by the square of the height in meters], &lt;18.5), or had hypervolemia, poorly controlled diabetes mellitus, or previous unacceptable side effects associated with glucocorticoid therapy, dexamethasone could be administered at a dose of 20 mg weekly at the discretion of their physician. Patients who were assigned to the daratumumab group received 1800 mg of daratumumab per 15 ml administered subcutaneously, coformulated with recombinant human hyaluronidase PH20, weekly in cycles 1 and 2, every 2 weeks in cycles 3 through 6, and every 4 weeks thereafter until disease progression, the start of subsequent therapy, or for a maximum of 24 cycles from the start of the trial, whichever occurred first. Details of pre- and postadministration medications that were given with daratumumab are provided in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-1-4"><h3>End Points and Assessments</h3><div role="paragraph">The primary end point was a hematologic complete response at the time of clinical cutoff in patients in the intention-to-treat population. The response had to be confirmed by a subsequent assessment during or after the trial treatment, as assessed by the independent review committee, whose members were unaware of the trial-group assignments. A hematologic complete response was defined as an involved free light-chain level less than the upper limit of the normal range with negative serum and urine immunofixation; normalization of the uninvolved free light-chain level or free light-chain ratio was not required to determine a complete response.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r24 r25" id="body-ref-r25-1" href-manipulated="true">5,24,25</a></sup> Patients who underwent randomization but were not treated, withdrew consent to participate, were lost to follow-up, or died before response assessment were considered to have not had a response. Secondary end points included survival free from major organ deterioration or hematologic progression (a composite end point including end-stage cardiac or renal failure, hematologic progression [assessed by the independent review committee], or death and analyzed with the use of an inverse-probability-of-censoring weighting method), organ response,<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26 r27" id="body-ref-r27-1" href-manipulated="true">26,27</a></sup> overall survival, hematologic complete response at 6 months, hematologic very good partial response or better, time to and duration of hematologic complete response, time to next treatment, and reduction in fatigue. Complete definitions of end points, disease evaluation timing, and definitions of hematologic and organ response are provided in the <a href="#ap2">Supplementary Appendix</a> (Additional Methods section and Tables S1 and S2).</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">The sample size for this trial was based on the assumption that the percentage of patients with a hematologic complete response would be 15 percentage points higher in the daratumumab group than in the control group; approximately 360 patients were required to provide 85% power to detect this difference (two-sided alpha level of 0.05). If the between-group difference for the primary end point was significant, the major secondary end points of survival free from major organ deterioration or hematologic progression and overall survival, as ordered here, were tested with the use of a hierarchical testing approach that controls the type I error.<sup><a href="#core-r28" role="doc-biblioref" data-xml-rid="r28" id="body-ref-r28" href-manipulated="true" aria-label="Reference 28">28</a></sup></div><div role="paragraph">Efficacy analyses were performed in the intention-to-treat population, which included all the patients who underwent randomization. The safety population comprised patients who received at least one dose of trial treatment. Between-group differences with respect to hematologic complete response were tested with the use of a stratified Cochran–Mantel–Haenszel test, and corresponding relative risk and odds ratios, 95% confidence intervals, and P values were reported. Time-to-event variables were evaluated with the Kaplan–Meier method. The primary analysis, reported here, occurred after all enrolled patients had been in the trial for at least 6 months. Full statistical methods are described in the <a href="#ap2">Supplementary Appendix</a>.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients and Treatment</h3><div role="paragraph">A total of 388 patients (195 in the daratumumab group and 193 in the control group) underwent randomization. The demographic and clinical characteristics of the patients at baseline were balanced between the groups (<a href="#t1">Table 1</a>). The median age was 64 years (range, 34 to 87), and the median time since diagnosis was 43 days (range, 5 to 1611). The median baseline difference between the involved and uninvolved free light-chain levels was 187 mg per liter (range, 1 to 9983). A total of 254 patients (65.5%) had two or more organs involved; 71.4% of the patients had heart involvement, and 59.0% had kidney involvement. The majority of patients (76.8%) were classified as having a cardiac stage of II or higher.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t1.jpg"><img src="/cms/10.1056/NEJMoa2028631/asset/cd975afe-f8f7-47ce-ae6b-36d20b85e91e/assets/images/large/nejmoa2028631_t1.jpg" height="3318" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Daratumumab Group<br>(N=195)</th><th class="txxr-borders">Control Group<br>(N=193)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading">Age</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Median (range) — yr</td><td class="xxxx-borders">62 (34–87)</td><td class="xxxr-borders">64 (35–86)</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Distribution — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">&lt;65 yr</td><td class="xxxx-borders">108 (55.4)</td><td class="xxxr-borders">97 (50.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">≥65 yr</td><td class="xxxx-borders shading">87 (44.6)</td><td class="xxxr-borders shading">96 (49.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Sex — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Male</td><td class="xxxx-borders shading">108 (55.4)</td><td class="xxxr-borders shading">117 (60.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Female</td><td class="xxxx-borders">87 (44.6)</td><td class="xxxr-borders">76 (39.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">ECOG performance-status score — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">0</td><td class="xxxx-borders">90 (46.2)</td><td class="xxxr-borders">71 (36.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">86 (44.1)</td><td class="xxxr-borders shading">106 (54.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">2</td><td class="xxxx-borders">19 (9.7)</td><td class="xxxr-borders">16 (8.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">AL isotype — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Lambda</td><td class="xxxx-borders">158 (81.0)</td><td class="xxxr-borders">149 (77.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Kappa</td><td class="xxxx-borders shading">37 (19.0)</td><td class="xxxr-borders shading">44 (22.8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">dFLC</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Median (range) — mg/liter</td><td class="xxxx-borders shading">200 (2–4749)</td><td class="xxxr-borders shading">186 (1–9983)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">&lt;50 mg/liter — no. (%)</td><td class="xxxx-borders">23 (11.8)</td><td class="xxxr-borders">13 (6.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">&lt;20 mg/liter — no. (%)</td><td class="xxxx-borders shading">10 (5.1)</td><td class="xxxr-borders shading">5 (2.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Median time since amyloidosis diagnosis (range) — days</td><td class="xxxx-borders">48 (8–1611)</td><td class="xxxr-borders">43 (5–1102)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Involved organs</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Median (range)</td><td class="xxxx-borders">2 (1–5)</td><td class="xxxr-borders">2 (1–6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Distribution — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Heart</td><td class="xxxx-borders">140 (71.8)</td><td class="xxxr-borders">137 (71.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Kidney</td><td class="xxxx-borders shading">115 (59.0)</td><td class="xxxr-borders shading">114 (59.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Liver</td><td class="xxxx-borders">15 (7.7)</td><td class="xxxr-borders">16 (8.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Other<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">127 (65.1)</td><td class="xxxr-borders shading">124 (64.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Cardiac stage — no. (%)<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">I</td><td class="xxxx-borders shading">47 (24.1)</td><td class="xxxr-borders shading">43 (22.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">II</td><td class="xxxx-borders">76 (39.0)</td><td class="xxxr-borders">80 (41.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">IIIA</td><td class="xxxx-borders shading">70 (35.9)</td><td class="xxxr-borders shading">64 (33.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">IIIB<a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">2 (1.0)</td><td class="xxxr-borders">6 (3.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Renal stage — no./total no. (%)<a href="#t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">I</td><td class="xxxx-borders">107/193 (55.4)</td><td class="xxxr-borders">101/193 (52.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">II</td><td class="xxxx-borders shading">67/193 (34.7)</td><td class="xxxr-borders shading">74/193 (38.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">III</td><td class="xxxx-borders">19/193 (9.8)</td><td class="xxxr-borders">18/193 (9.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Creatinine clearance — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">&lt;60 ml/min</td><td class="xxxx-borders">69 (35.4)</td><td class="xxxr-borders">62 (32.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">≥60 ml/min</td><td class="xxxx-borders shading">126 (64.6)</td><td class="xxxr-borders shading">131 (67.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Residence in a country that typically offers transplantation for patients with AL amyloidosis — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Yes</td><td class="xxxx-borders shading">147 (75.4)</td><td class="xxxr-borders shading">146 (75.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">No</td><td class="xxxx-borders">48 (24.6)</td><td class="xxxr-borders">47 (24.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Median NT-proBNP level (range) — ng/liter</td><td class="xxxx-borders shading">1388.6 (51–10,182)</td><td class="xxxr-borders shading">1746.0 (51–12,950)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging03" data-xml-align="left">Median estimated GFR (range) — ml/min/1.73 m<sup>2</sup></td><td class="xbxx-borders">77.8 (21–126)</td><td class="xbxr-borders">76.2 (20–121)</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Disease Characteristics of the Patients at Baseline (Intention-to-Treat Population).<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">The intention-to-treat population included all the patients who underwent randomization. AL denotes immunoglobulin light chain, dFLC the difference between involved and uninvolved free light-chain levels, GFR glomerular filtration rate, and NT-proBNP N-terminal pro–B-type natriuretic peptide.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with 0 indicating no symptoms and higher scores indicating increasing disability.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Data are based on immunofixation or light-chain measurement.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">Other includes gastrointestinal tract, lung, peripheral nervous system, autonomic nervous system, and soft tissue.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">Cardiac stage was classified in accordance with the European modification of the staging system of the Mayo Clinic.<sup><a href="#core-r29" role="doc-biblioref" data-xml-rid="r29" id="body-ref-r29" href-manipulated="true" aria-label="Reference 29">29</a></sup> Cardiac stage was based on two biomarker risk factors — NT-proBNP and high-sensitivity cardiac troponin T — that were assessed at a central laboratory.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">All the patients had a cardiac stage of I, II, or IIIA at screening; however, some converted to stage IIIB at cycle 1, day 1 (results determined by the central laboratory were made available only after cycle 1, day 1).</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t1fn7" role="paragraph">Renal stage is based on the combination of estimated GFR and urinary protein excretion.<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27" id="body-ref-r27-2" href-manipulated="true" aria-label="Reference 27">27</a></sup></div></div></div></figcaption></figure></div><div role="paragraph">Among the 388 patients who underwent randomization, 381 (193 in the daratumumab group and 188 in the control group) received at least one dose of trial treatment (Fig. S2). At the time of clinical data cutoff for the primary analysis (February 14, 2020), a total of 52 patients (26.9%) in the daratumumab group and 68 patients (36.2%) in the control group had discontinued the intervention before the protocol-defined completion of treatment. In the control group, 121 patients (64.4%) received six cycles of treatment as specified by the protocol. In the daratumumab group, 159 patients (82.4%) completed six cycles of trial treatment, and 149 (77.2%) continued single-agent subcutaneous daratumumab after completing the first six treatment cycles; at the time of analysis, 141 of 195 patients (72.3%) were continuing to receive daratumumab. Dose reductions were similar in the daratumumab group and the control group (cyclophosphamide, 17.6% and 13.8%, respectively; bortezomib, 25.9% and 19.7%; dexamethasone, 27.5% and 27.7%; daratumumab dose reductions were not permitted). The median duration of therapy was 9.6 months in the daratumumab group and 5.3 months in the control group.</div></section><section id="sec-2-2"><h3>Efficacy</h3><div role="paragraph"><a id="exam-tint-two-b"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="two-b">With a median follow-up of 11.4 months (range, 0.03 to 21.3), 104 patients (53.3%) in the daratumumab group and 35 patients (18.1%) in the control group had a hematologic complete response (<a href="#t2">Table 2</a>). This difference was significant (relative risk ratio, 2.9; 95% confidence interval [CI], 2.1 to 4.1; odds ratio, 5.1; 95% CI, 3.2 to 8.2; P&lt;0.001 for both comparisons).</span> The percentages of patients with a hematologic complete response in prespecified subgroups showed consistent benefit in the daratumumab group (<a href="#f1">Figure 1</a>). Landmark analysis of hematologic complete response at 6 months showed percentages consistent with overall hematologic complete response (49.7% in the daratumumab group vs. 14.0% in the control group; relative risk ratio, 3.5; 95% CI, 2.4 to 5.2; odds ratio, 6.1; 95% CI, 3.7 to 10.0; P&lt;0.001 for both comparisons). <a id="exam-tint-two-c"></a><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="two-c">The median time to hematologic complete response was 60 days in the daratumumab group and 85 days in the control group.</span> The percentage of patients who had a hematologic very good partial response or better was 78.5% in the daratumumab group and 49.2% in the control group (relative risk ratio, 1.6; 95% CI, 1.4 to 1.9; odds ratio, 3.8; 95% CI, 2.4 to 5.9). An involved free light-chain level of 20 mg or less per liter was observed more frequently among patients in the daratumumab group than among those in the control group (70.5% vs. 20.2%); similar outcomes were observed for a difference between the involved and uninvolved free light-chain levels of less than 10 mg per liter (63.3% vs. 29.5%) (<a href="#t2">Table 2</a> and Fig. S3).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028631_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028631_f1.jpg"><img src="/cms/10.1056/NEJMoa2028631/asset/89c65f21-b9b1-49ce-b821-7df431674e5e/assets/images/large/nejmoa2028631_f1.jpg" height="2910" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Prespecified Subgroup Analysis of Hematologic Complete Response.</div><div class="notes"><div role="doc-footnote">Shown are the results of an analysis of hematologic complete response in prespecified subgroups in the intention-to-treat population, which included all the patients who underwent randomization. Patients in the daratumumab group were assigned to receive treatment with daratumumab, bortezomib, cyclophosphamide, and dexamethasone; patients in the control group were assigned to receive treatment with bortezomib, cyclophosphamide, and dexamethasone. Race was reported by the patient. Cardiac stage is based on the combination of N-terminal pro–B-type natriuretic peptide and high-sensitivity cardiac troponin T. Patients who had a cardiac stage of IIIB at screening were excluded from the trial according to the protocol. The category of cardiac stage IIIA or IIIB includes patients who had a cardiac stage of IIIA at screening but progressed to stage IIIB at cycle 1, day 1. Renal stage is based on the combination of estimated glomerular filtration rate and urinary protein excretion. Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with 0 indicating no symptoms and higher scores indicating increasing disability. High cytogenetic risk was defined by fluorescence in situ hybridization (FISH) testing as a t(4;14) mutation, t(14;16) mutation, or 17p deletion or by karyotype testing as a t(4;14) mutation or 17p deletion. AL denotes immunoglobulin light chain, and NE could not be estimated.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t2.jpg"><img src="/cms/10.1056/NEJMoa2028631/asset/cdaeace3-bf24-4d71-bd53-66ebaf9cdde9/assets/images/large/nejmoa2028631_t2.jpg" height="2327" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Response</th><th class="txxx-borders">Daratumumab Group <br>(N=195)</th><th class="txxx-borders">Control Group <br>(N=193)</th><th class="txxr-borders">P Value<a href="#t2fn2" role="doc-noteref">†</a></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading">Hematologic response</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Any response — no. of patients</td><td class="xxxx-borders">179</td><td class="xxxx-borders">148</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders shading">91.8 (87.0–95.2)</td><td class="xxxx-borders shading">76.7 (70.1–82.5)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Complete response — no. of patients<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">104<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">35<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders shading">53.3 (46.1–60.5)</td><td class="xxxx-borders shading">18.1 (13.0–24.3)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Very good partial response or better — no. (%)</td><td class="xxxx-borders">153 (78.5)</td><td class="xxxx-borders">95 (49.2)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Very good partial response — no. (%)</td><td class="xxxx-borders shading">49 (25.1)</td><td class="xxxx-borders shading">60 (31.1)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Partial response — no. (%)</td><td class="xxxx-borders">26 (13.3)</td><td class="xxxx-borders">53 (27.5)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">No response — no. (%)</td><td class="xxxx-borders shading">8 (4.1)</td><td class="xxxx-borders shading">38 (19.7)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Progressive disease — no. (%)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Response could not be evaluated — no. (%)</td><td class="xxxx-borders shading">8 (4.1)</td><td class="xxxx-borders shading">7 (3.6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Involved free light-chain level ≤20 mg/liter — no./total no. (%)<a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">136/193 (70.5)</td><td class="xxxx-borders">39/193 (20.2)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">dFLC &lt;10 mg/liter — no./total no. (%)<a href="#t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">119/188 (63.3)</td><td class="xxxx-borders shading">56/190 (29.5)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Cardiac response at 6 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">No. of patients who could be evaluated<a href="#t2fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">118</td><td class="xxxx-borders shading">117</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Percent with a response (95% CI)</td><td class="xxxx-borders">41.5 (32.5–51.0)</td><td class="xxxx-borders">22.2 (15.1–30.8)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Renal response at 6 mo</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">No. of patients who could be evaluated<a href="#t2fn8" role="doc-noteref">††</a></td><td class="xxxx-borders">117</td><td class="xxxx-borders">113</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13 shading" data-xml-align="left">Percent with a response (95% CI)</td><td class="xbxx-borders shading">53.0 (43.5–62.3)</td><td class="xbxx-borders shading">23.9 (16.4–32.8)</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="caption">Summary of Overall Confirmed Hematologic Responses and Cardiac and Renal Responses at 6 Months.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Hematologic response was assessed centrally in the intention-to-treat population. Organ response in patients with measurable organ involvement was assessed by an independent review committee whose members were unaware of the trial-group assignments, according to previously validated criteria that are outlined in the protocol.<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26 r27" id="body-ref-r27-3" href-manipulated="true">26,27</a></sup> CI denotes confidence interval.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">The P value was calculated with the use of the Cochran–Mantel–Haenszel chi-square test.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">Complete response was based on consensus criteria with clarifications as specified in the trial protocol that required confirmation by the independent review committee. Complete response was defined as negative immunofixation and normalization of the free light-chain ratio without confirmation,<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26-3" href-manipulated="true" aria-label="Reference 26">26</a></sup> a reduction in the absolute involved free light-chain level to 20 mg or less per liter,<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25-2" href-manipulated="true" aria-label="Reference 25">25</a></sup> and a reduction in the dFLC to less than 10 mg per liter.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5-3" href-manipulated="true" aria-label="Reference 5">5</a></sup></div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">Of the 104 patients who had a hematologic complete response in the daratumumab group, 4 patients died while in complete response and no patients with a complete response had a relapse. Of the 35 patients who had a hematologic complete response in the control group, 2 patients died while in complete response and 2 patients had a relapse after a complete response.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t2fn5" role="paragraph">Excluded are 2 patients with an involved free light-chain level of 20 mg or less per liter at baseline (both in the daratumumab group).</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t2fn6" role="paragraph">Excluded are 10 patients with a dFLC of less than 10 mg per liter at baseline (7 in the daratumumab group and 3 in the control group).</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t2fn7" role="paragraph">Patients who could be evaluated for cardiac response were defined as those with a baseline NT-proBNP value of 650 ng or more per liter or a baseline New York Heart Association (NYHA) class of III or IV. In addition, patients must have received at least one administration of trial treatment and have had at least one postbaseline NT-proBNP measurement (if the baseline NT-proBNP was ≥650 ng per liter) or NYHA function evaluation (if the baseline NYHA class was III or IV).</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="t2fn8" role="paragraph">Patients who could be evaluated for renal response were defined as those with a baseline urinary protein excretion of more than 0.5 g per day. In addition, patients must have received at least one administration of trial treatment and had at least one postbaseline measurement of urinary protein excretion.</div></div></div></figcaption></figure></div><div role="paragraph">Among patients who could be evaluated for cardiac response (118 in the daratumumab group and 117 in the control group), the percentage who had a cardiac response at 6 months was 41.5% in the daratumumab group and 22.2% in the control group (<a href="#t2">Table 2</a>); cardiac progression at 6 months was observed in 2.5% and 7.7% of the patients, respectively. Among patients who could be evaluated for renal response (117 in the daratumumab group and 113 in the control group), the percentage who had a renal response at 6 months was 53.0% in the daratumumab group and 23.9% in the control group (<a href="#t2">Table 2</a>); renal progression at 6 months was observed in 4.3% and 11.5% of the patients, respectively.</div><div role="paragraph"><a id="exam-tint-two-a"></a><span id="tint5" class="named-content" data-type="exam-tint" data-answer-ids="two-a">Survival free from major organ deterioration or hematologic progression was longer in the daratumumab group than in the control group (hazard ratio for major organ deterioration, hematologic progression, or death, 0.58; 95% CI, 0.36 to 0.93; P=0.02) (<a href="#f2">Figure 2</a>).</span> Hematologic progression occurred in 8 patients (4.1%) in the daratumumab group and in 25 patients (13.0%) in the control group. Survival free from major organ deterioration, hematologic progression, or subsequent treatment was also longer in the daratumumab group than in the control group (hazard ratio for major organ deterioration, hematologic progression, subsequent treatment, or death, 0.39; 95% CI, 0.27 to 0.56). A detailed listing of all observed events of major organ deterioration, hematologic progression, subsequent treatment, or death according to treatment group is provided in Table S3, and results of supportive analyses (including without censoring for subsequent treatment) are provided in Table S4.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028631_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028631_f2.jpg"><img src="/cms/10.1056/NEJMoa2028631/asset/ca494efe-7239-4761-91c1-451404ae1791/assets/images/large/nejmoa2028631_f2.jpg" height="1958" width="2231" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Kaplan–Meier Estimates of Survival Free from Major Organ Deterioration or Hematologic Progression.</div><div class="notes"><div role="doc-footnote">Shown are the results of the Kaplan–Meier estimates of survival from major organ deterioration or hematologic progression among patients in the intention-to-treat population. Major organ deterioration was defined as end-stage cardiac or renal failure.</div></div></figcaption></figure></div><div role="paragraph">A total of 19 of 193 patients (9.8%) in the daratumumab group and 79 of 188 patients (42.0%) in the control group received non–cross-resistant subsequent therapy. Of the 79 patients in the control group who received non–cross-resistant subsequent therapy, 48 (61%) received intravenous daratumumab as monotherapy or in combination with other therapies. A total of 13 of 193 patients (6.7%) in the daratumumab group and 20 of 188 patients (10.6%) in the control group received subsequent autologous stem-cell transplantation. Overall survival did not differ substantially between the two groups at the time of this analysis (Fig. S4).</div></section><section id="sec-2-3"><h3>Safety</h3><div role="paragraph"><a id="exam-tint-three-a"></a><a id="exam-tint-three-b"></a><a id="exam-tint-three-c"></a><a id="exam-tint-three-d"></a><span id="tint6" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-b three-c three-d">The most common adverse events of any grade (occurring in &gt;25% of the patients in either group) and of grade 3 or 4 (occurring in ≥5% of the patients in either group) are summarized in <a href="#t3">Table 3</a>. The most common adverse events of grade 3 or 4 were lymphopenia (13.0% in the daratumumab group and 10.1% in the control group), pneumonia (7.8% and 4.3%, respectively), cardiac failure (6.2% and 4.8%), diarrhea (5.7% and 3.7%), syncope (5.2% and 6.4%), neutropenia (5.2% and 2.7%), peripheral edema (3.1% and 5.9%), and hypokalemia (1.6% and 5.3%). The incidence of grade 3 or 4 infections was 16.6% in the daratumumab group and 10.1% in the control group.</span></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t3.jpg"><img src="/cms/10.1056/NEJMoa2028631/asset/3ecd9eea-2f02-4059-bd05-75149f3fcceb/assets/images/large/nejmoa2028631_t3.jpg" height="1307" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="2"><span>Daratumumab Group<br>(N=193)</span></th><th class="txxr-borders" colspan="2"><span>Control Group<br>(N=188)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 3 or 4</th><th class="xxxx-borders">Any Grade</th><th class="xxxr-borders">Grade 3 or 4</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="4"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Diarrhea</td><td class="xxxx-borders shading">69 (35.8)</td><td class="xxxx-borders shading">11 (5.7)</td><td class="xxxx-borders shading">57 (30.3)</td><td class="xxxr-borders shading">7 (3.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Peripheral edema</td><td class="xxxx-borders">69 (35.8)</td><td class="xxxx-borders">6 (3.1)</td><td class="xxxx-borders">68 (36.2)</td><td class="xxxr-borders">11 (5.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">66 (34.2)</td><td class="xxxx-borders shading">3 (1.6)</td><td class="xxxx-borders shading">54 (28.7)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Peripheral sensory neuropathy</td><td class="xxxx-borders">60 (31.1)</td><td class="xxxx-borders">5 (2.6)</td><td class="xxxx-borders">37 (19.7)</td><td class="xxxr-borders">4 (2.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Fatigue</td><td class="xxxx-borders shading">52 (26.9)</td><td class="xxxx-borders shading">8 (4.1)</td><td class="xxxx-borders shading">53 (28.2)</td><td class="xxxr-borders shading">6 (3.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Nausea</td><td class="xxxx-borders">52 (26.9)</td><td class="xxxx-borders">3 (1.6)</td><td class="xxxx-borders">52 (27.7)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders shading">50 (25.9)</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">21 (11.2)</td><td class="xxxr-borders shading">1 (0.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Lymphopenia</td><td class="xxxx-borders">36 (18.7)</td><td class="xxxx-borders">25 (13.0)</td><td class="xxxx-borders">28 (14.9)</td><td class="xxxr-borders">19 (10.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hypokalemia</td><td class="xxxx-borders shading">24 (12.4)</td><td class="xxxx-borders shading">3 (1.6)</td><td class="xxxx-borders shading">28 (14.9)</td><td class="xxxr-borders shading">10 (5.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Neutropenia</td><td class="xxxx-borders">21 (10.9)</td><td class="xxxx-borders">10 (5.2)</td><td class="xxxx-borders">12 (6.4)</td><td class="xxxr-borders">5 (2.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Pneumonia</td><td class="xxxx-borders shading">21 (10.9)</td><td class="xxxx-borders shading">15 (7.8)</td><td class="xxxx-borders shading">12 (6.4)</td><td class="xxxr-borders shading">8 (4.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Syncope</td><td class="xxxx-borders">14 (7.3)</td><td class="xxxx-borders">10 (5.2)</td><td class="xxxx-borders">12 (6.4)</td><td class="xxxr-borders">12 (6.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01 shading" data-xml-align="left">Cardiac failure<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xbxx-borders shading">18 (9.3)</td><td class="xbxx-borders shading">12 (6.2)</td><td class="xbxx-borders shading">14 (7.4)</td><td class="xbxr-borders shading">9 (4.8)</td></tr></tbody></table></div><figcaption><div class="caption">Most Common Adverse Events during Treatment (Safety Population).<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">The safety population included patients who received at least one administration of trial treatment. Shown are adverse events of any grade that occurred in more than 25% of the patients in either group and grade 3 or 4 events that occurred in at least 5% of the patients in either group.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">This category includes overall and congestive cardiac failure.</div></div></div></figcaption></figure></div><div role="paragraph">Serious adverse events occurred in 43.0% of the patients in the daratumumab group and in 36.2% of those in the control group; the most common serious adverse event was pneumonia, which occurred in 7.3% and 4.8% of the patients in the respective groups. The percentage of patients who had adverse events that led to discontinuation of trial treatment was 4.1% in the daratumumab group and 4.3% in the control group.</div><div role="paragraph">A total of 56 deaths occurred during the trial: 27 in the daratumumab group and 29 in the control group (1 patient in the control group died before receiving trial treatment). Deaths during the first 60 days of treatment occurred in 13 patients in each group. Death was attributed to adverse events in 23 patients (11.9%) in the daratumumab group and in 14 patients (7.4%) in the control group. Deaths that were attributed to disease progression were less frequent in the daratumumab group than in the control group (1.0% vs. 4.8%), as were deaths for other reasons (1.0% vs. 2.7%). The majority of adverse events leading to death and of deaths overall occurred in patients with cardiac involvement at baseline. All the patients who died owing to cardiac disorders had cardiac involvement at baseline.</div><div role="paragraph">Systemic administration-related reactions to daratumumab occurred in 14 patients (7.3%); all such reactions were of grade 1 or 2. The majority of these patients (86%) had a reaction at the first daratumumab administration. The median time to onset was 1.3 hours (range, 0.2 to 7.3). Local injection-site reactions to any agent occurred in 54 patients (28.0%) in the daratumumab group and in 45 patients (23.9%) in the control group. A total of 21 patients (10.9%) in the daratumumab group had local injection-site reactions related to daratumumab, all of which were of grade 1 or 2. Details of administration- and injection-related reactions are provided in Table S5.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph"><span id="tint7" class="named-content" data-type="exam-tint" data-answer-ids="two-b">In this phase 3 trial involving patients with newly diagnosed AL amyloidosis, subcutaneous daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone resulted in a significantly higher frequency of a hematologic complete response than bortezomib, cyclophosphamide, and dexamethasone alone.</span> Hematologic responses were deeper and occurred more rapidly in the daratumumab group. Results were consistent for patients with a cardiac stage of III and those with t(11;14) translocation (<a href="#f1">Figure 1</a>).</div><div role="paragraph">Definitions of hematologic response in patients with AL amyloidosis are evolving. All definitions of complete response that are associated with improved overall survival showed the superiority of daratumumab when analyzed, including complete response defined as negative immunofixation and normalization of the free light-chain ratio without confirmation (International Society of Amyloidosis) (Table S6),<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26-4" href-manipulated="true" aria-label="Reference 26">26</a></sup> a reduction in the absolute involved free light-chain level to 20 mg or less per liter,<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25 r30 r31" id="body-ref-r31" href-manipulated="true">25,30,31</a></sup> and a reduction in the difference between the involved and uninvolved free light-chain levels to less than 10 mg per liter.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r32" id="body-ref-r32" href-manipulated="true">5,32</a></sup> Reductions in the absolute involved free light-chain level to 20 mg or less per liter and in the difference between the involved and uninvolved free light-chain levels to less than 10 mg per liter occurred more rapidly among patients in the daratumumab group (Fig. S3).</div><div role="paragraph">A recent clarification to International Society of Amyloidosis criteria<sup><a href="#core-r33" role="doc-biblioref" data-xml-rid="r33" id="body-ref-r33" href-manipulated="true" aria-label="Reference 33">33</a></sup> defines complete response as negative immunofixation and a free light-chain ratio within the reference range or abnormal free light-chain ratio if the uninvolved free light-chain level is higher than the involved free light-chain level; when these criteria are used, results of the ANDROMEDA trial are consistent with those of the primary analysis that used the definition of complete response specified in our trial (54.4% in the daratumumab group vs. 26.9% in the control group; relative risk ratio, 2.0; 95% CI, 1.5 to 2.6; odds ratio, 3.1; 95% CI, 2.1 to 4.8; P&lt;0.001 for both comparisons) (Table S6). Given the importance of rapid and deep hematologic response to improve the outcomes of patients with AL amyloidosis, these results are promising; outcomes with first-line bortezomib-based regimens have consistently resulted in frequencies of hematologic complete response of approximately 24%.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4 r5 r26" id="body-ref-r26-5" href-manipulated="true">3–5,26</a></sup> In addition, 48 patients in the control group went on to receive daratumumab-based therapy in the next line of treatment. Longer follow-up is needed to determine whether the addition of daratumumab to standard therapy improves overall survival.</div><div role="paragraph"><a id="exam-tint-two-d"></a><span id="tint8" class="named-content" data-type="exam-tint" data-answer-ids="two-d">The percentages of patients who had a cardiac or renal response were substantially higher in the daratumumab group than in the control group, an important finding given that organ responses are also a predictor of improved survival.</span><sup><a href="#core-r34" role="doc-biblioref" data-xml-rid="r34 r35" id="body-ref-r35" href-manipulated="true">34,35</a></sup> Patients in the daratumumab group were more likely than those in the control group to have survival free from major organ deterioration or hematologic progression, an objective measure of clinically relevant and observable end points for patients with AL amyloidosis. We acknowledge that the maintenance therapy received by patients in the daratumumab group may affect outcomes such as survival free from major organ deterioration or hematologic progression and survival free from major organ deterioration, hematologic progression, or subsequent therapy. Despite this longer duration of therapy, analysis without censoring for subsequent therapy still showed significantly longer survival free from major organ deterioration or hematologic progression in the daratumumab group than in the control group (Table S4).</div><div role="paragraph">The safety profiles of daratumumab and bortezomib, cyclophosphamide, and dexamethasone in this trial were consistent with their known profiles and the underlying disease. <span id="tint9" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-b three-c three-d">As in previous trials of daratumumab involving patients with multiple myeloma, an increase in hematologic adverse events and infections was observed.</span><sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14-2" href-manipulated="true" aria-label="Reference 14">14</a></sup> Peripheral neuropathy was more frequent in the daratumumab group than in the control group, but the incidence of grade 3 or 4 peripheral sensory neuropathy was low and similar in the two groups. In a multisystem disease such as AL amyloidosis, it may be difficult to differentiate between disease manifestations and treatment-related complications, and adverse events from multidrug regimens represent a challenge for these patients, who are often frail and have multiorgan involvement. When adjusted for exposure to trial treatment, the incidence of overall and grade 3 or 4 adverse events was lower in the daratumumab group than in the control group (Table S7). The incidences of all deaths and deaths due to adverse events within 60 days after the first dose of trial treatment were balanced between the treatment groups. Overall, deaths in both groups were primarily due to AL amyloidosis–related cardiomyopathy, reported either as an adverse event or as progression of organ disease.</div><div role="paragraph">From a clinical standpoint, subcutaneous daratumumab provides important advantages for the population of patients with AL amyloidosis. These include reduced systemic administration-related reactions and negligible volume of administration.<sup><a href="#core-r36" role="doc-biblioref" data-xml-rid="r36" id="body-ref-r36" href-manipulated="true" aria-label="Reference 36">36</a></sup></div><div role="paragraph">In this prospective, randomized trial involving patients with newly diagnosed AL amyloidosis, the addition of subcutaneous daratumumab to bortezomib, cyclophosphamide, and dexamethasone resulted in significantly better outcomes.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">Janssen Research and Development</span>.</div><div role="paragraph">Dr. Kastritis reports receiving grant support and advisory board fees from Amgen, advisory board fees and travel support from Genesis Pharma, grant support, advisory board fees, and travel support from Janssen Global Services, and advisory board fees from Pfizer and Takeda Oncology; Dr. Palladini, receiving advisory board fees and presentation honoraria from Janssen Global Services and honoraria from Pfizer and Siemens; Dr. Minnema, receiving advisory board fees, paid to her institution, from Alnylam Pharmaceuticals and Takeda Oncology, travel support from Celgene and F. Hoffmann–La Roche, and consulting fees, paid to her institution, from Gilead Sciences and Johnson &amp; Johnson Health Care Systems; Dr. Wechalekar, receiving advisory board fees from Alexion Pharmaceuticals, Caelum Biosciences, GlaxoSmithKline, and Janssen Biotech and lecture fees from Celgene and Takeda Oncology; Dr. Jaccard, receiving lecture fees and advisory board fees from Janssen Biotech; Dr. Lee, receiving grant support and consulting fees from Amgen, Celgene, GlaxoSmithKline, Janssen Biotech, and Takeda Oncology, consulting fees from Genentech and Sanofi-Aventis, and grant support from Regeneron Pharmaceuticals; Dr. Sanchorawala, receiving advisory board fees from AbbVie, Janssen Biotech, and Regeneron Pharmaceuticals; Dr. Gibbs, receiving advisory board fees from AbbVie and Akcea Therapeutics, grant support, paid to the Australian Amyloidosis Network, and lecture fees from Amgen, grant support, paid to the Australian Amyloidosis Network, and advisory board fees from Bristol-Myers Squibb and Pfizer, steering committee fees from Eidos Therapeutics, and grant support, paid to Eastern Health, and advisory board fees from Janssen Biotech; Dr. Mollee, receiving advisory board fees, paid to his institution, from Bristol-Myers Squibb, Caelum Biosciences, Celgene, Pfizer, and Takeda Oncology and grant support and advisory board fees, paid to his institution, from Janssen Pharmaceuticals; Dr. Venner, receiving advisory board fees from Akcea Therapeutics, Amgen Canada, Celgene, GlaxoSmithKline, Janssen Biotech, and Sanofi Pasteur and advisory board fees and end-point review committee fees from Takeda Oncology; Dr. Schönland, receiving advisory board fees from Janssen Biotech and Janssen Global Services, grant support, paid to University Hospital Heidelberg, from Sanofi Pasteur, and advisory board fees and travel support from Takeda Oncology; Dr. K. Kim, receiving grant support from Celgene and Janssen Global Services; Dr. Cibeira, receiving advisory board fees from Amgen and Janssen Biotech; Dr. Beksac, receiving advisory board fees, paid to Ankara University, from Amgen and Bristol-Myers Squibb and fees for serving on a speakers bureau and advisory board fees, paid to Ankara University, from Janssen Global Services, Sanofi Pasteur Biologics, and Takeda Oncology; Dr. Libby, receiving grant support, paid to the University of Washington, from the Academic Myeloma Consortium, BeiGene USA, Celgene, Genentech USA, GlaxoSmithKline, Janssen Biotech, and Prothena Biosciences and consulting fees from Adaptive Biotechnologies; Dr. Valent, receiving lecture fees and teaching fees from Amgen, Celgene, and Takeda Oncology; Dr. Hungria, receiving consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen Biotech, Sanofi Genzyme, and Takeda Oncology; Dr. Wong, receiving consulting fees from Amgen, fees for serving as principal investigator from Bristol-Myers Squibb, Fortis, Genentech USA, GlaxoSmithKline, and Janssen Biotech, and advisory board fees from Sanofi US Services; Dr. Rosenzweig, receiving advisory board fees from AbbVie Biotherapeutics, fees for serving on a speakers bureau and an educational council from Akcea Therapeutics, fees for serving on a speakers bureau from Bristol-Myers Squibb, Celgene, and Takeda Pharmaceutical, and advisory board fees and fees for serving on a speakers bureau from Janssen Biotech; Dr. Bumma, receiving advisory board fees from Alnylam Pharmaceuticals and fees for serving on a speakers bureau from Amgen and Sanofi US Services; Dr. Dimopoulos, receiving consulting fees from Amgen, BeiGene, Bristol-Myers Squibb, Janssen Global Services, and Takeda Oncology; Dr. Bhutani, receiving grant support from Sanofi US Services; Dr. Zonder, receiving consulting fees from Alnylam Pharmaceuticals, Amgen, Caelum Biosciences, Intellia Therapeutics, Janssen Biotech, Oncopeptides, Regeneron Pharmaceuticals, and Takeda Oncology and research support from Bristol-Myers Squibb; Dr. Lam, receiving advisory board fees from AbbVie, Amgen, Bristol-Myers Squibb, and Sanofi Pasteur and advisory board fees, lecture fees, and fees for an education program from Janssen Biotech; Dr. Song, receiving advisory board fees and fees for serving as a trial investigator from Amgen Canada, Bristol-Myers Squibb Canada, and Janssen Biotech and fees for serving as a trial investigator from Takeda Oncology; Dr. Hansen, receiving advisory board fees from Bristol-Myers Squibb, GlaxoSmithKline, Janssen Biotech, Sanofi Genzyme, and Takeda Oncology; Dr. Manier, receiving grant support, paid to Institut pour la Recherche sur le Cancer de Lille, from AbbVie, grant support and advisory board fees, paid to Institut pour la Recherche sur le Cancer de Lille, from Amgen and Celgene, and grant support, advisory board fees, paid to Journées d’Hématologie Clinique Lilloise, and travel support from Janssen Biotech; Dr. Jamroziak, receiving grant support, paid to the Polish Myeloma Consortium, grant support, paid to the Polish Adult Leukemia Group, and advisory board fees and lecture fees from Janssen Global Services; Dr. Crusoe, receiving research support from Janssen Biotech; Dr. Ahmadi, being employed by and owning stock and stock options in Genmab; Dr. Tran, being employed by and owning stock and stock options in Janssen Pharmaceuticals; Ms. Vasey, being employed by and owning stock in Janssen Pharmaceuticals; Ms. Tromp, being employed by and owning stock and stock options in Janssen Biotech; Dr. Schecter, being employed by and owning stock in Johnson &amp; Johnson; Dr. Weiss, being employed by Janssen Research and Development and owning stock in Johnson &amp; Johnson; Dr. Zhuang, being employed by and owning stock in Janssen Research and Development; Dr. Vermeulen, being employed by and owning stock in Johnson &amp; Johnson Health Care Systems; Dr. Merlini, receiving advisory board fees from Janssen Global Services; and Dr. Comenzo, receiving steering committee fees from Janssen Biotech, receiving advisory board fees from Karyopharm Therapeutics, receiving fees for serving on a data and safety monitoring committee from Sanofi-Aventis, and holding patent WO2016187546A1 on anti-CD38 antibodies for treatment of light-chain amyloidosis and other CD38-positive hematologic cancers. No other potential conflict of interest relevant to this article was reported.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the patients who volunteered to participate in this trial and staff members at the trial sites who cared for them; the members of the independent data monitoring committee (C. Ola Landgren, Niels van de Donk, and Yu Shyr), the members of the independent review committee (Rafat Abonour, Anita D’Souza, Angela Dispenzieri, Shaji Kumar, Michael O’Dwyer, and Saad Usmani), and Elise Blankenship and Melissa Brunckhorst of Cello Health Communications/MedErgy for medical editorial and writing assistance with an earlier version of the manuscript.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap0" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Research Summary</span> <span class="core-filename">(nejmoa2028631_research-summary.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2028631/suppl_file/nejmoa2028631_research-summary.pdf" download="nejmoa2028631_research-summary.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2028631_research-summary.pdf" data-doi="10.1056/NEJMoa2028631">Download</a></li><li>3.31 MB</li></ul></div></div><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2028631_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2028631/suppl_file/nejmoa2028631_protocol.pdf" download="nejmoa2028631_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2028631_protocol.pdf" data-doi="10.1056/NEJMoa2028631">Download</a></li><li>7.15 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2028631_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2028631/suppl_file/nejmoa2028631_appendix.pdf" download="nejmoa2028631_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2028631_appendix.pdf" data-doi="10.1056/NEJMoa2028631">Download</a></li><li>1.26 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2028631_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2028631/suppl_file/nejmoa2028631_disclosures.pdf" download="nejmoa2028631_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2028631_disclosures.pdf" data-doi="10.1056/NEJMoa2028631">Download</a></li><li>1.74 MB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2028631_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2028631/suppl_file/nejmoa2028631_data-sharing.pdf" download="nejmoa2028631_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2028631_data-sharing.pdf" data-doi="10.1056/NEJMoa2028631">Download</a></li><li>71.06 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. <em>Nat Rev Dis Primers</em> 2018;4:38-38.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41572-018-0034-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30361521/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000448497700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Systemic+immunoglobulin+light+chain+amyloidosis.&amp;publication_year=2018&amp;journal=Nat+Rev+Dis+Primers&amp;pages=38-38&amp;doi=10.1038%2Fs41572-018-0034-3&amp;pmid=30361521" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r1-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] most frequently to the heart and kidneys. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] leads to progressive disability and death. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Weiss BM, Hebreo J, Cordaro DV, et al. Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis. <em>J Clin Oncol</em> 2014;32:2699-2704.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2013.50.0892" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25024082/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000341562600007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Increased+serum+free+light+chains+precede+the+presentation+of+immunoglobulin+light+chain+amyloidosis.&amp;publication_year=2014&amp;journal=J+Clin+Oncol&amp;pages=2699-2704&amp;doi=10.1200%2FJCO.2013.50.0892&amp;pmid=25024082" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. <em>Blood</em> 2015;126:612-615.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2015-01-620302" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25987656/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000358871900012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+European+collaborative+study+of+cyclophosphamide%2C+bortezomib%2C+and+dexamethasone+in+upfront+treatment+of+systemic+AL+amyloidosis.&amp;publication_year=2015&amp;journal=Blood&amp;pages=612-615&amp;doi=10.1182%2Fblood-2015-01-620302&amp;pmid=25987656" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] leads to progressive disability and death. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] is the most commonly used regimen. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] of the Mayo Clinic Cardiac Staging System), </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] complete response of approximately 24%. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. <em>J Clin Oncol</em> 2020;38:3252-3260.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.20.01285" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32730181/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000587963400004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bortezomib%2C+melphalan%2C+and+dexamethasone+for+light-chain+amyloidosis.&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;pages=3252-3260&amp;doi=10.1200%2FJCO.20.01285&amp;pmid=32730181" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] is the most commonly used regimen. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] complete response of approximately 24%. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Manwani R, Cohen O, Sharpley F, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. <em>Blood</em> 2019;134:2271-2280.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019000834" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31578202/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000506630200008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+prospective+observational+study+of+915+patients+with+systemic+AL+amyloidosis+treated+with+upfront+bortezomib.&amp;publication_year=2019&amp;journal=Blood&amp;pages=2271-2280&amp;doi=10.1182%2Fblood.2019000834&amp;pmid=31578202" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] is the most commonly used regimen. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] required to determine a complete response. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t2" role="menuitem" data-target="#fv-body-ref-r5-3"><i aria-hidden="true" class="icon-return"></i><span>c [...] in the dFLC to less than 10 mg per liter. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r32" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] levels to less than 10 mg per liter. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] complete response of approximately 24%. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Muchtar E, Gertz MA, Kumar SK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <em>Blood</em> 2017;129:2111-2119.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2016-11-751628" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28126928/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000399008200015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Improved+outcomes+for+newly+diagnosed+AL+amyloidosis+between+2000+and+2014%3A+cracking+the+glass+ceiling+of+early+death.&amp;publication_year=2017&amp;journal=Blood&amp;pages=2111-2119&amp;doi=10.1182%2Fblood-2016-11-751628&amp;pmid=28126928" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">de Weers M, Tai Y-T, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. <em>J Immunol</em> 2011;186:1840-1848.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.1003032" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21187443/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000286381200064" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Daratumumab%2C+a+novel+therapeutic+human+CD38+monoclonal+antibody%2C+induces+killing+of+multiple+myeloma+and+other+hematological+tumors.&amp;publication_year=2011&amp;journal=J+Immunol&amp;pages=1840-1848&amp;doi=10.4049%2Fjimmunol.1003032&amp;pmid=21187443" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Overdijk MB, Jansen JHM, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor-mediated cross-linking. <em>J Immunol</em> 2016;197:807-813.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.1501351" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27316683/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000380338600014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+therapeutic+CD38+monoclonal+antibody+daratumumab+induces+programmed+cell+death+via+Fc%CE%B3+receptor-mediated+cross-linking.&amp;publication_year=2016&amp;journal=J+Immunol&amp;pages=807-813&amp;doi=10.4049%2Fjimmunol.1501351&amp;pmid=27316683" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Overdijk MB, Verploegen S, Bögels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. <em>MAbs</em> 2015;7:311-321.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/19420862.2015.1007813" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25760767/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000351244000004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antibody-mediated+phagocytosis+contributes+to+the+anti-tumor+activity+of+the+therapeutic+antibody+daratumumab+in+lymphoma+and+multiple+myeloma.&amp;publication_year=2015&amp;journal=MAbs&amp;pages=311-321&amp;doi=10.1080%2F19420862.2015.1007813&amp;pmid=25760767" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Lammerts van Bueren J, Jakobs D, Kaldenhoven N, et al. Direct <i>in vitro</i> comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. <em>Blood</em> 2014;124:3474-3474 (<a href="https://ashpublications.org/blood/article/124/21/3474/97703/Direct-in-Vitro-Comparison-of-Daratumumab-with" target="_blank">https://ashpublications.org/blood/article/124/21/3474/97703/Direct-in-Vitro-Comparison-of-Daratumumab-with</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.V124.21.3474.3474" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000349242706125" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Direct+in+vitro+comparison+of+daratumumab+with+surrogate+analogs+of+CD38+antibodies+MOR03087%2C+SAR650984+and+Ab79.&amp;publication_year=2014&amp;journal=Blood&amp;pages=3474-3474&amp;doi=10.1182%2Fblood.V124.21.3474.3474" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38<sup>+</sup> immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. <em>Blood</em> 2016;128:384-394.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2015-12-687749" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27222480/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000384078200012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Daratumumab+depletes+CD38%2B+immune+regulatory+cells%2C+promotes+T-cell+expansion%2C+and+skews+T-cell+repertoire+in+multiple+myeloma.&amp;publication_year=2016&amp;journal=Blood&amp;pages=384-394&amp;doi=10.1182%2Fblood-2015-12-687749&amp;pmid=27222480" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Adams HC III, Stevenaert F, Krejcik J, et al. High-parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action. <em>Cytometry A</em> 2019;95:279-289.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/cyto.a.23693" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30536810/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000460979500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=High-parameter+mass+cytometry+evaluation+of+relapsed%2Frefractory+multiple+myeloma+patients+treated+with+daratumumab+demonstrates+immune+modulation+as+a+novel+mechanism+of+action.&amp;publication_year=2019&amp;journal=Cytometry+A&amp;pages=279-289&amp;doi=10.1002%2Fcyto.a.23693&amp;pmid=30536810" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Casneuf T, Adams HC III, van de Donk NWCJ, et al. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. <em>Leukemia</em> 2021;35:573-584.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41375-020-0855-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32457357/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000559642100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Deep+immune+profiling+of+patients+treated+with+lenalidomide+and+dexamethasone+with+or+without+daratumumab.&amp;publication_year=2021&amp;journal=Leukemia&amp;pages=573-584&amp;doi=10.1038%2Fs41375-020-0855-4&amp;pmid=32457357" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content"><em>Darzalex (daratumumab)</em>. Horsham, PA: Janssen Biotech, August 2020 (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Darzalex+%28daratumumab%29&amp;publication_year=2020" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] regimens for multiple myeloma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] adverse events and infections was observed. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Kaufman GP, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. <em>Blood</em> 2017;130:900-902.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2017-01-763599" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28615223/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000407779500011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Daratumumab+yields+rapid+and+deep+hematologic+responses+in+patients+with+heavily+pretreated+AL+amyloidosis.&amp;publication_year=2017&amp;journal=Blood&amp;pages=900-902&amp;doi=10.1182%2Fblood-2017-01-763599&amp;pmid=28615223" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Khouri J, Kin A, Thapa B, et al. Daratumumab proves safe and highly effective in AL amyloidosis. <em>Br J Haematol</em> 2019;185:342-344.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.15455" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29938774/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000467975200021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Daratumumab+proves+safe+and+highly+effective+in+AL+amyloidosis.&amp;publication_year=2019&amp;journal=Br+J+Haematol&amp;pages=342-344&amp;doi=10.1111%2Fbjh.15455&amp;pmid=29938774" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Abeykoon JP, Zanwar S, Dispenzieri A, et al. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <em>Leukemia</em> 2019;33:531-536.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41375-018-0262-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30267007/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457857300026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Daratumumab-based+therapy+in+patients+with+heavily-pretreated+AL+amyloidosis.&amp;publication_year=2019&amp;journal=Leukemia&amp;pages=531-536&amp;doi=10.1038%2Fs41375-018-0262-2&amp;pmid=30267007" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Roussel M, Merlini G, Chevret S, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. <em>Blood</em> 2020;135:1531-1540.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019004369" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32108228/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000534368300006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+prospective+phase+2+trial+of+daratumumab+in+patients+with+previously+treated+systemic+light-chain+amyloidosis.&amp;publication_year=2020&amp;journal=Blood&amp;pages=1531-1540&amp;doi=10.1182%2Fblood.2019004369&amp;pmid=32108228" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Sanchorawala V, Sarosiek S, Schulman A, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. <em>Blood</em> 2020;135:1541-1547.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019004436" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31978210/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000534368300007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety%2C+tolerability%2C+and+response+rates+of+daratumumab+in+relapsed+AL+amyloidosis%3A+results+of+a+phase+2+study.&amp;publication_year=2020&amp;journal=Blood&amp;pages=1541-1547&amp;doi=10.1182%2Fblood.2019004436&amp;pmid=31978210" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Kimmich CR, Terzer T, Benner A, et al. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. <em>Blood</em> 2020;135:1517-1530.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019003633" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32107537/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000534368300005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Daratumumab+for+systemic+AL+amyloidosis%3A+prognostic+factors+and+adverse+outcome+with+nephrotic-range+albuminuria.&amp;publication_year=2020&amp;journal=Blood&amp;pages=1517-1530&amp;doi=10.1182%2Fblood.2019003633&amp;pmid=32107537" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Milani P, Fazio F, Basset M, et al. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate. <em>Am J Hematol</em> 2020;95:900-905.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ajh.25828" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32282971/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000529618900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=High+rate+of+profound+clonal+and+renal+responses+with+daratumumab+treatment+in+heavily+pre-treated+patients+with+light+chain+%28AL%29+amyloidosis+and+high+bone+marrow+plasma+cell+infiltrate.&amp;publication_year=2020&amp;journal=Am+J+Hematol&amp;pages=900-905&amp;doi=10.1002%2Fajh.25828&amp;pmid=32282971" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. <em>Blood</em> 2020;136:71-80.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019004460" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32244252/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000550379200011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Daratumumab+plus+CyBorD+for+patients+with+newly+diagnosed+AL+amyloidosis%3A+safety+run-in+results+of+ANDROMEDA.&amp;publication_year=2020&amp;journal=Blood&amp;pages=71-80&amp;doi=10.1182%2Fblood.2019004460&amp;pmid=32244252" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <em>Lancet Oncol</em> 2014;15(12):e538-e548.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(14)70442-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25439696/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000344546400022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=International+Myeloma+Working+Group+updated+criteria+for+the+diagnosis+of+multiple+myeloma.&amp;publication_year=2014&amp;journal=Lancet+Oncol&amp;pages=e538-e548&amp;doi=10.1016%2FS1470-2045%2814%2970442-5&amp;pmid=25439696" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Sidana S, Dispenzieri A, Murray DL, et al. Revisiting complete response in light chain amyloidosis. <em>Leukemia</em> 2020;34:1472-1475.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41375-019-0664-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31772296/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000529704000026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Revisiting+complete+response+in+light+chain+amyloidosis.&amp;publication_year=2020&amp;journal=Leukemia&amp;pages=1472-1475&amp;doi=10.1038%2Fs41375-019-0664-9&amp;pmid=31772296" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Muchtar E, Dispenzieri A, Leung N, et al. Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <em>Leukemia</em> 2019;33:527-531.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r25" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41375-018-0258-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30258095/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457857300025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Optimizing+deep+response+assessment+for+AL+amyloidosis+using+involved+free+light+chain+level+at+end+of+therapy%3A+failure+of+the+serum+free+light+chain+ratio.&amp;publication_year=2019&amp;journal=Leukemia&amp;pages=527-531&amp;doi=10.1038%2Fs41375-018-0258-y&amp;pmid=30258095" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r25" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r25-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] required to determine a complete response. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t2" role="menuitem" data-target="#fv-body-ref-r25-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] level to 20 mg or less per liter, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r31" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] level to 20 mg or less per liter, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. <em>J Clin Oncol</em> 2012;30:4541-4549.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r26" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2011.37.7614" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23091105/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000312815000021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=New+criteria+for+response+to+treatment+in+immunoglobulin+light+chain+amyloidosis+based+on+free+light+chain+measurement+and+cardiac+biomarkers%3A+impact+on+survival+outcomes.&amp;publication_year=2012&amp;journal=J+Clin+Oncol&amp;pages=4541-4549&amp;doi=10.1200%2FJCO.2011.37.7614&amp;pmid=23091105" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r26" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r27-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] weighting method), organ response, </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t2" role="menuitem" data-target="#fv-body-ref-r26-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] criteria that are outlined in the protocol. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t2" role="menuitem" data-target="#fv-body-ref-r26-3"><i aria-hidden="true" class="icon-return"></i><span>c [...] light-chain ratio without confirmation, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] Society of Amyloidosis) (Table S6), </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] complete response of approximately 24%. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. <em>Blood</em> 2014;124:2325-2332.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r27" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2014-04-570010" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25115890/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000347454400009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+staging+system+for+renal+outcome+and+early+markers+of+renal+response+to+chemotherapy+in+AL+amyloidosis.&amp;publication_year=2014&amp;journal=Blood&amp;pages=2325-2332&amp;doi=10.1182%2Fblood-2014-04-570010&amp;pmid=25115890" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r27" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r27-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] weighting method), organ response, </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t1" role="menuitem" data-target="#fv-body-ref-r27-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] GFR and urinary protein excretion. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t2" role="menuitem" data-target="#fv-body-ref-r27-3"><i aria-hidden="true" class="icon-return"></i><span>c [...] criteria that are outlined in the protocol. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Tang DI, Geller NL. Closed testing procedures for group sequential clinical trials with multiple endpoints. <em>Biometrics</em> 1999;55:1188-1192.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.0006-341X.1999.01188.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11315066/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000084218000027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Closed+testing+procedures+for+group+sequential+clinical+trials+with+multiple+endpoints.&amp;publication_year=1999&amp;journal=Biometrics&amp;pages=1188-1192&amp;doi=10.1111%2Fj.0006-341X.1999.01188.x&amp;pmid=11315066" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? <em>Blood</em> 2016;128:159-168.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2016-01-629790" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27053535/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000383830000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=What+is+new+in+diagnosis+and+management+of+light+chain+amyloidosis%3F&amp;publication_year=2016&amp;journal=Blood&amp;pages=159-168&amp;doi=10.1182%2Fblood-2016-01-629790&amp;pmid=27053535" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Sarosiek S, Zheng L, Sloan JM, Quillen K, Brauneis D, Sanchorawala V. Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis. <em>Blood Cancer J</em> 2020;10:88-88.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41408-020-00354-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32873776/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000569421400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparing+measures+of+hematologic+response+after+high-dose+melphalan+and+stem+cell+transplantation+in+AL+amyloidosis.&amp;publication_year=2020&amp;journal=Blood+Cancer+J&amp;pages=88-88&amp;doi=10.1038%2Fs41408-020-00354-7&amp;pmid=32873776" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Milani P, Basset M, Nuvolone M, et al. Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy. <em>Blood Cancer J</em> 2020;10:90-90.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41408-020-00355-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32873771/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000569421400003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Indicators+of+profound+hematologic+response+in+AL+amyloidosis%3A+complete+response+remains+the+goal+of+therapy.&amp;publication_year=2020&amp;journal=Blood+Cancer+J&amp;pages=90-90&amp;doi=10.1038%2Fs41408-020-00355-6&amp;pmid=32873771" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Muchtar E, Gertz MA, Lacy MQ, et al. Refining amyloid complete hematological response: quantitative serum free light chains superior to ratio. <em>Am J Hematol</em> 2020;95:1280-1287.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ajh.25940" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32681737/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000561955500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Refining+amyloid+complete+hematological+response%3A+quantitative+serum+free+light+chains+superior+to+ratio.&amp;publication_year=2020&amp;journal=Am+J+Hematol&amp;pages=1280-1287&amp;doi=10.1002%2Fajh.25940&amp;pmid=32681737" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="r33" class="citations"><div class="citation"><div class="citation-content">Palladini G, Schönland SO, Sanchorawala V, et al. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. <em>Amyloid</em> 2021;28:1-2.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/13506129.2020.1868810" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33410355/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000605715300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clarification+on+the+definition+of+complete+haematologic+response+in+light-chain+%28AL%29+amyloidosis.&amp;publication_year=2021&amp;journal=Amyloid&amp;pages=1-2&amp;doi=10.1080%2F13506129.2020.1868810&amp;pmid=33410355" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="r34" class="citations"><div class="citation"><div class="citation-content">Kaufman GP, Dispenzieri A, Gertz MA, et al. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. <em>Am J Hematol</em> 2015;90:181-186.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ajh.23898" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25388651/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000349889300009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Kinetics+of+organ+response+and+survival+following+normalization+of+the+serum+free+light+chain+ratio+in+AL+amyloidosis.&amp;publication_year=2015&amp;journal=Am+J+Hematol&amp;pages=181-186&amp;doi=10.1002%2Fajh.23898&amp;pmid=25388651" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="r35" class="citations"><div class="citation"><div class="citation-content">Muchtar E, Dispenzieri A, Leung N, et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <em>Leukemia</em> 2018;32:2240-2249.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41375-018-0060-x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29581546/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000446171800013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Depth+of+organ+response+in+AL+amyloidosis+is+associated+with+improved+survival%3A+grading+the+organ+response+criteria.&amp;publication_year=2018&amp;journal=Leukemia&amp;pages=2240-2249&amp;doi=10.1038%2Fs41375-018-0060-x&amp;pmid=29581546" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="r36" class="citations"><div class="citation"><div class="citation-content">Mateos M-V, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. <em>Lancet Haematol</em> 2020;7(5):e370-e380.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2352-3026(20)30070-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32213342/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000530901900013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Subcutaneous+versus+intravenous+daratumumab+in+patients+with+relapsed+or+refractory+multiple+myeloma+%28COLUMBA%29%3A+a+multicentre%2C+open-label%2C+non-inferiority%2C+randomised%2C+phase+3+trial.&amp;publication_year=2020&amp;journal=Lancet+Haematol&amp;pages=e370-e380&amp;doi=10.1016%2FS2352-3026%2820%2930070-3&amp;pmid=32213342" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/385/1"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">385</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">1</span></span> • <span property="datePublished">July 1, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">46</span>-<span property="pageEnd">58</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2021 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: June 30, 2021</div><div><b class="core-label">Published in issue</b>: July 1, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/leukemia-lymphoma" alt="View article keyword Leukemia/Lymphoma" data-interactiontype="article_recirculation_click">Leukemia/Lymphoma</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/treatments-in-oncology" alt="View article keyword Treatments in Oncology" data-interactiontype="article_recirculation_click">Treatments in Oncology</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Efstathios</span> <span property="familyName">Kastritis</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Giovanni</span> <span property="familyName">Palladini</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Monique C.</span> <span property="familyName">Minnema</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ashutosh D.</span> <span property="familyName">Wechalekar</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Arnaud</span> <span property="familyName">Jaccard</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Hans C.</span> <span property="familyName">Lee</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Vaishali</span> <span property="familyName">Sanchorawala</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Simon</span> <span property="familyName">Gibbs</span>, <span property="honorificSuffix">M.B., B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Peter</span> <span property="familyName">Mollee</span>, <span property="honorificSuffix">M.B., B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Christopher P.</span> <span property="familyName">Venner</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jin</span> <span property="familyName">Lu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Stefan</span> <span property="familyName">Schönland</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Moshe E.</span> <span property="familyName">Gatt</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kenshi</span> <span property="familyName">Suzuki</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kihyun</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">M. Teresa</span> <span property="familyName">Cibeira</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Meral</span> <span property="familyName">Beksac</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Edward</span> <span property="familyName">Libby</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jason</span> <span property="familyName">Valent</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Vania</span> <span property="familyName">Hungria</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sandy W.</span> <span property="familyName">Wong</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Michael</span> <span property="familyName">Rosenzweig</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Naresh</span> <span property="familyName">Bumma</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Antoine</span> <span property="familyName">Huart</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Meletios A.</span> <span property="familyName">Dimopoulos</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Divaya</span> <span property="familyName">Bhutani</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Adam J.</span> <span property="familyName">Waxman</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Stacey A.</span> <span property="familyName">Goodman</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jeffrey A.</span> <span property="familyName">Zonder</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Selay</span> <span property="familyName">Lam</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kevin</span> <span property="familyName">Song</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Timon</span> <span property="familyName">Hansen</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Salomon</span> <span property="familyName">Manier</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Wilfried</span> <span property="familyName">Roeloffzen</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Krzysztof</span> <span property="familyName">Jamroziak</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Fiona</span> <span property="familyName">Kwok</span>, <span property="honorificSuffix">M.B., B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Chihiro</span> <span property="familyName">Shimazaki</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jin-Seok</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Edvan</span> <span property="familyName">Crusoe</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Tahamtan</span> <span property="familyName">Ahmadi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">NamPhuong</span> <span property="familyName">Tran</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Xiang</span> <span property="familyName">Qin</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sandra Y.</span> <span property="familyName">Vasey</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Brenda</span> <span property="familyName">Tromp</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jordan M.</span> <span property="familyName">Schecter</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Brendan M.</span> <span property="familyName">Weiss</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sen H.</span> <span property="familyName">Zhuang</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jessica</span> <span property="familyName">Vermeulen</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Giampaolo</span> <span property="familyName">Merlini</span>, <span property="honorificSuffix">M.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Raymond L.</span> <span property="familyName">Comenzo</span>, <span property="honorificSuffix">M.D.</span></span>, for <span property="author" typeof="Person">the ANDROMEDA Trial Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens (E.K., M.A.D.); the Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and the Department of Molecular Medicine, University of Pavia, Pavia, Italy (G.P., G.M.); the Department of Hematology, University Medical Center Utrecht, University Utrecht, Utrecht (M.C.M.), the Amyloidosis Center of Expertise, University of Groningen, University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (B.T., J. Vermeulen) — all in the Netherlands; University College London, London (A.D.W.); Centre Hospitalier Universitaire (CHU) and Reference Center for AL Amyloidosis, Limoges (A.J.), Département de Néphrologie et Transplantation d’Organes, Centre de Référence des Maladies Rénales Rares, Hôpital Rangueil, CHU de Toulouse, Toulouse (A.H.), and the Department of Hematology, CHU Lille, University of Lille, Lille (S.M.) — all in France; the Department of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston (H.C.L.); the Amyloidosis Center, Boston University School of Medicine and Boston Medical Center (V.S.), and the Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center (R.L.C.) — both in Boston; the Victorian and Tasmanian Amyloidosis Service, Department of Haematology, Monash University Eastern Health Clinical School, Melbourne, VIC (S.G.), the Department of Haematology, Princess Alexandra Hospital and University of Queensland Medical School, Brisbane (P.M.), and the Department of Clinical Haematology, Westmead Hospital, Westmead, NSW (F.K.) — all in Australia; Cross Cancer Institute, University of Alberta, Edmonton (C.P.V.), the Division of Hematology, London Health Sciences Centre, London Regional Cancer Program, Western University, London, ON (S.L.), and the Division of Hematology, Vancouver General Hospital, BC Cancer, University of British Columbia, Vancouver (K. Song) — all in Canada; Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Collaborative Innovation Center of Hematology, Beijing (J.L.); Medical Department V (Hematology/Oncology/Rheumatology), Amyloidosis Center, Heidelberg University Hospital, Heidelberg (S.S.), and Hämatologisch-Onkologische Praxis Altona, Hamburg (T.H.) — both in Germany; the Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem (M.E.G.); the Department of Hematology, Japanese Red Cross Medical Center, Tokyo (K. Suzuki), and the Department of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto (C.S.) — both in Japan; the Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (K.K.), and the Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine (J.-S.K.) — both in Seoul, South Korea; the Amyloidosis and Myeloma Unit, Hospital Clinic of Barcelona, August Pi i Sunyer Biomedical Research Institute, Barcelona (M.T.C.); the Department of Hematology, Ankara University, Ankara, Turkey (M.B.); the Division of Medical Oncology, Department of Medicine, University of Washington, Seattle (E.L.); the Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland (J. Valent), and the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (N.B.) — both in Ohio; Clínica São Germano, São Paulo (V.H.), and Clinica CEHON, Rede D’Or Oncologia, Salvador (E.C.) — both in Brazil; the Department of Medicine, University of California, San Francisco, San Francisco (S.W.W.), the Department of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte (M.R.), and Janssen Research and Development, Los Angeles (N.T.) — all in California; the Department of Internal Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York (D.B.); the Penn Amyloidosis Program, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.J.W.), and Janssen Research and Development, Spring House (X.Q., S.Y.V., B.M.W.) — both in Pennsylvania; Vanderbilt University Medical Center and Veterans Affairs Tennessee Valley Healthcare System, Nashville (S.A.G.); the Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit (J.A.Z.); the Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland (K.J.); and Genmab US, Princeton (T.A.), and Janssen Research and Development, Raritan (J.M.S., S.H.Z.) — both in New Jersey.</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Merlini at Fondazione IRCCS Policlinico San Matteo and the Department of Molecular Medicine, University of Pavia, Viale Golgi 19, 27100 Pavia, Italy, or at <a href="mailto:gmerlini@unipv.it">gmerlini@unipv.it</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A complete list of investigators in the ANDROMEDA trial is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div><div role="doc-footnote"><div id="fn2" role="paragraph">Drs. Merlini and Comenzo contributed equally to this article.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">418</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2028631" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="e55e0658-bdc6-e5a0-3fdf-cf30cc411eb4"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108473846" style="display:inline-block;">
                <img alt="Article has an altmetric score of 166" src="https://badges.altmetric.com/?size=320&amp;score=166&amp;types=mbvctfud" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108473846">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_e55e0658-bdc6-e5a0-3fdf-cf30cc411eb4" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108473846&amp;tab=news">
          Picked up by <b>7</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108473846&amp;tab=blogs">
          Blogged by <b>2</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108473846&amp;tab=policy-documents">
          Referenced in <b>2</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108473846&amp;tab=twitter">
          Posted by <b>133</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108473846&amp;tab=patents">
          Referenced in <b>1</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108473846&amp;tab=facebook">
          On <b>4</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108473846&amp;tab=wikipedia">
          Referenced in <b>1</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #94DB5E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108473846&amp;tab=video">
          On <b>1</b> videos
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108473846&amp;tab=guidelines">
          Referenced in <b>4</b> clinical guideline sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #70B1FF;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108473846&amp;tab=bluesky">
          Referenced by <b>4</b> Bluesky users
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>342</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d68a6c257f6224-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2028631"> <input type="hidden" name="downloadFileName" value="csp_385_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2028631%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-1" data-lazyload="false" data-total="418" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Lukas Damian Weberling, </li><li class="list-inline-item cited-by__entry__author">Andreas Ochs, </li><li class="list-inline-item cited-by__entry__author">Mitchel Benovoy, </li><li class="list-inline-item cited-by__entry__author">Fabian aus dem Siepen, </li><li class="list-inline-item cited-by__entry__author">Janek Salatzki, </li><li class="list-inline-item cited-by__entry__author">Evangelos Giannitsis, </li><li class="list-inline-item cited-by__entry__author">Chong Duan, </li><li class="list-inline-item cited-by__entry__author">Kevin Maresca, </li><li class="list-inline-item cited-by__entry__author">Yao Zhang, </li><li class="list-inline-item cited-by__entry__author">Jan Möller, </li><li class="list-inline-item cited-by__entry__author">Silke Friedrich, </li><li class="list-inline-item cited-by__entry__author">Stefan Schönland, </li><li class="list-inline-item cited-by__entry__author">Benjamin Meder, </li><li class="list-inline-item cited-by__entry__author">Matthias G. Friedrich, </li><li class="list-inline-item cited-by__entry__author">Norbert Frey, </li><li class="list-inline-item cited-by__entry__author">Florian André, </li></ul><span class="cited-by__entry__title">Machine Learning to Automatically Differentiate Hypertrophic Cardiomyopathy, Cardiac Light Chain, and Cardiac Transthyretin Amyloidosis: A Multicenter CMR Study, </span><span class="cited-by__entry__series-title">Circulation: Cardiovascular Imaging, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1161/CIRCIMAGING.124.017761" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1161/CIRCIMAGING.124.017761</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1161/CIRCIMAGING.124.017761" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Nicole K. Bart, </li><li class="list-inline-item cited-by__entry__author">Giada Bianchi, </li><li class="list-inline-item cited-by__entry__author">Sarah A.M. Cuddy, </li><li class="list-inline-item cited-by__entry__author">Parag Goyal, </li><li class="list-inline-item cited-by__entry__author">Jan M. Griffin, </li><li class="list-inline-item cited-by__entry__author">Scott L. Hummel, </li><li class="list-inline-item cited-by__entry__author">Peter Macdonald, </li><li class="list-inline-item cited-by__entry__author">Mathew Maurer, </li><li class="list-inline-item cited-by__entry__author">Elyn Montgomery, </li><li class="list-inline-item cited-by__entry__author">Michael G. Nanne, </li><li class="list-inline-item cited-by__entry__author">Ariela R. Orkaby, </li><li class="list-inline-item cited-by__entry__author">Vaishali Sanchorawala, </li><li class="list-inline-item cited-by__entry__author">Abdulla A. Damluji, </li></ul><span class="cited-by__entry__title">Cardiac Amyloidosis in Older Adults With a Focus on Frailty, </span><span class="cited-by__entry__series-title">JACC: Advances, </span><span class="cited-by__entry__volume"><strong>4</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(101784), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jacadv.2025.101784" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jacadv.2025.101784</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jacadv.2025.101784" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Naidong Pang, </li><li class="list-inline-item cited-by__entry__author">Ying Tian, </li><li class="list-inline-item cited-by__entry__author">Hongjie Chi, </li><li class="list-inline-item cited-by__entry__author">Xiaohong Fu, </li><li class="list-inline-item cited-by__entry__author">Xin Li, </li><li class="list-inline-item cited-by__entry__author">Shuyu Wang, </li><li class="list-inline-item cited-by__entry__author">Feifei Pan, </li><li class="list-inline-item cited-by__entry__author">Dongying Wang, </li><li class="list-inline-item cited-by__entry__author">Lin Xu, </li><li class="list-inline-item cited-by__entry__author">Jingyi Luo, </li><li class="list-inline-item cited-by__entry__author">Aijun Liu, </li><li class="list-inline-item cited-by__entry__author">XingPeng Liu, </li></ul><span class="cited-by__entry__title">Development and validation of an early prediction model for cardiac death risk in patients with light chain amyloidosis: a multicenter study, </span><span class="cited-by__entry__series-title">Cardio-Oncology, </span><span class="cited-by__entry__volume"><strong>11</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s40959-025-00342-5" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s40959-025-00342-5</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s40959-025-00342-5" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Cristina Chimenti, </li><li class="list-inline-item cited-by__entry__author">Attilio Iacovoni, </li><li class="list-inline-item cited-by__entry__author">Andrea Montalto, </li><li class="list-inline-item cited-by__entry__author">Michele Emdin, </li><li class="list-inline-item cited-by__entry__author">Iacopo Olivotto, </li><li class="list-inline-item cited-by__entry__author">Cristina Basso, </li><li class="list-inline-item cited-by__entry__author">Benedetta Carla De Chiara, </li><li class="list-inline-item cited-by__entry__author">Irene Bottillo, </li><li class="list-inline-item cited-by__entry__author">Claudio Mario Ciampi, </li><li class="list-inline-item cited-by__entry__author">Santo Dellegrottaglie, </li><li class="list-inline-item cited-by__entry__author">Massimo Di Marco, </li><li class="list-inline-item cited-by__entry__author">Piero Gentile, </li><li class="list-inline-item cited-by__entry__author">Francesca Girolami, </li><li class="list-inline-item cited-by__entry__author">Paola Grammatico, </li><li class="list-inline-item cited-by__entry__author">Maria Iascone, </li><li class="list-inline-item cited-by__entry__author">Eluisa La Franca, </li><li class="list-inline-item cited-by__entry__author">Carla Lofiego, </li><li class="list-inline-item cited-by__entry__author">Andrea Matteucci, </li><li class="list-inline-item cited-by__entry__author">Daniele Pasqualucci, </li><li class="list-inline-item cited-by__entry__author">Samuele Pentiricci, </li><li class="list-inline-item cited-by__entry__author">Enrica Perugini, </li><li class="list-inline-item cited-by__entry__author">Maurizio Pieroni, </li><li class="list-inline-item cited-by__entry__author">Giovanni Quarta, </li><li class="list-inline-item cited-by__entry__author">Federica Re, </li><li class="list-inline-item cited-by__entry__author">Laura Scelsi, </li><li class="list-inline-item cited-by__entry__author">Giancarlo Todiere, </li><li class="list-inline-item cited-by__entry__author">Maria Alfarano, </li><li class="list-inline-item cited-by__entry__author">Monica De Gaspari, </li><li class="list-inline-item cited-by__entry__author">Claudio Bilato, </li><li class="list-inline-item cited-by__entry__author">Marco Corda, </li><li class="list-inline-item cited-by__entry__author">Leonardo De Luca, </li><li class="list-inline-item cited-by__entry__author">Giovanna Geraci, </li><li class="list-inline-item cited-by__entry__author">Massimo Milli, </li><li class="list-inline-item cited-by__entry__author">Alessandro Navazio, </li><li class="list-inline-item cited-by__entry__author">Vittorio Pascale, </li><li class="list-inline-item cited-by__entry__author">Carmine Riccio, </li><li class="list-inline-item cited-by__entry__author">Pietro Scicchitano, </li><li class="list-inline-item cited-by__entry__author">Emanuele Tizzani, </li><li class="list-inline-item cited-by__entry__author">Michele Massimo Gulizia, </li><li class="list-inline-item cited-by__entry__author">Federico Nardi, </li><li class="list-inline-item cited-by__entry__author">Domenico Gabrielli, </li><li class="list-inline-item cited-by__entry__author">Furio Colivicchi, </li><li class="list-inline-item cited-by__entry__author">Massimo Grimaldi, </li><li class="list-inline-item cited-by__entry__author">Fabrizio Oliva, </li></ul><span class="cited-by__entry__title">ANMCO position paper ‘Hypertrophic cardiomyopathy: from diagnosis to treatment’, </span><span class="cited-by__entry__series-title">European Heart Journal Supplements, </span><span class="cited-by__entry__volume"><strong>27</strong>, </span><span class="cited-by__entry__issue">Supplement_5, </span><span class="cited-by__entry__page-range">(v256-v279), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1093/eurheartjsupp/suaf077" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1093/eurheartjsupp/suaf077</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1093/eurheartjsupp/suaf077" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Louie Cao, </li><li class="list-inline-item cited-by__entry__author">Gloria J Hong, </li><li class="list-inline-item cited-by__entry__author">Michael Abiragi, </li><li class="list-inline-item cited-by__entry__author">Jonathan Le, </li><li class="list-inline-item cited-by__entry__author">P Ryan Tacon, </li><li class="list-inline-item cited-by__entry__author">I-Min Chiu, </li><li class="list-inline-item cited-by__entry__author">Jignesh Patel, </li><li class="list-inline-item cited-by__entry__author">Lily K Stern, </li><li class="list-inline-item cited-by__entry__author">Chathuri Daluwatte, </li><li class="list-inline-item cited-by__entry__author">David Ouyang, </li><li class="list-inline-item cited-by__entry__author">Piero Ricchiuto, </li></ul><span class="cited-by__entry__title">Ratio of interventricular septal thickness to global longitudinal strain accurately identifies cardiac amyloidosis, </span><span class="cited-by__entry__series-title">Open Heart, </span><span class="cited-by__entry__volume"><strong>12</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__page-range">(e003120), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1136/openhrt-2024-003120" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1136/openhrt-2024-003120</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1136/openhrt-2024-003120" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yuko Tashima, </li><li class="list-inline-item cited-by__entry__author">Koshi Setoyama, </li><li class="list-inline-item cited-by__entry__author">Takehiro Higashi, </li><li class="list-inline-item cited-by__entry__author">Aya Nawata, </li><li class="list-inline-item cited-by__entry__author">Fumihiro Tanaka, </li></ul><span class="cited-by__entry__title">Interdisciplinary Approach to Diagnostic Challenges: A Case Study of Cardiac Amyloid Light-Chain (AL) Amyloidosis, Multiple Myeloma, and Ductal Carcinoma In Situ, </span><span class="cited-by__entry__series-title">Cureus, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.7759/cureus.83299" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.7759/cureus.83299</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.7759/cureus.83299" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Mallika Lal, </li><li class="list-inline-item cited-by__entry__author">Ahmad Masri, </li><li class="list-inline-item cited-by__entry__author">Adam Ioannou, </li><li class="list-inline-item cited-by__entry__author">Marianna Fontana, </li><li class="list-inline-item cited-by__entry__author">Yevgeniy Brailovsky, </li><li class="list-inline-item cited-by__entry__author">Mathew S. Maurer, </li></ul><span class="cited-by__entry__title">To screen or not to screen for transthyretin cardiac amyloidosis, </span><span class="cited-by__entry__series-title">Journal of Nuclear Cardiology, </span><span class="cited-by__entry__volume"><strong>47</strong>, </span><span class="cited-by__entry__page-range">(102122), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.nuclcard.2024.102122" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.nuclcard.2024.102122</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.nuclcard.2024.102122" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yen-Wen Wu, </li><li class="list-inline-item cited-by__entry__author">Chao-Hung Wei, </li><li class="list-inline-item cited-by__entry__author">Yen-Hung Lin, </li><li class="list-inline-item cited-by__entry__author">Shang-Yi Huang, </li><li class="list-inline-item cited-by__entry__author">Yen-Wen Liu, </li><li class="list-inline-item cited-by__entry__author">Tran-Der Tan, </li><li class="list-inline-item cited-by__entry__author">Wen-Chung Yu, </li><li class="list-inline-item cited-by__entry__author">Chia-Jen Liu, </li><li class="list-inline-item cited-by__entry__author">Chung-Lieh Hung, </li><li class="list-inline-item cited-by__entry__author">Po-Shen Ko, </li><li class="list-inline-item cited-by__entry__author">Ning-I Yang, </li><li class="list-inline-item cited-by__entry__author">Shih-Feng Cho, </li><li class="list-inline-item cited-by__entry__author">Chun-Yao Huang, </li><li class="list-inline-item cited-by__entry__author">Chun-Kai Liao, </li><li class="list-inline-item cited-by__entry__author">Chieh-Lin Jerry Teng, </li><li class="list-inline-item cited-by__entry__author">Tsai-Yun Chen, </li><li class="list-inline-item cited-by__entry__author">Wen-Jone Chen, </li><li class="list-inline-item cited-by__entry__author">Bor-Sheng Ko, </li></ul><span class="cited-by__entry__title">Joint position statement of the diagnosis and management of light chain amyloidosis and light chain cardiac amyloidosis by the Taiwan Society of Cardiology (TSOC) and the Hematology Society of Taiwan (HST), </span><span class="cited-by__entry__series-title">Journal of the Formosan Medical Association, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jfma.2025.05.006" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jfma.2025.05.006</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jfma.2025.05.006" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Sharmila Dorbala, </li><li class="list-inline-item cited-by__entry__author">Rosalyn Adigun, </li><li class="list-inline-item cited-by__entry__author">Kevin M. Alexander, </li><li class="list-inline-item cited-by__entry__author">Michela Brambatti, </li><li class="list-inline-item cited-by__entry__author">Sarah A.M. Cuddy, </li><li class="list-inline-item cited-by__entry__author">Angela Dispenzieri, </li><li class="list-inline-item cited-by__entry__author">Preston Dunnmon, </li><li class="list-inline-item cited-by__entry__author">Michele Emdin, </li><li class="list-inline-item cited-by__entry__author">Omar F. Abou Ezzeddine, </li><li class="list-inline-item cited-by__entry__author">Rodney H. Falk, </li><li class="list-inline-item cited-by__entry__author">Mariana Fontana, </li><li class="list-inline-item cited-by__entry__author">Justin L. Grodin, </li><li class="list-inline-item cited-by__entry__author">Spencer Guthrie, </li><li class="list-inline-item cited-by__entry__author">Michael Jerosch-Herold, </li><li class="list-inline-item cited-by__entry__author">A. Alex Hofling, </li><li class="list-inline-item cited-by__entry__author">Kristen Hsu, </li><li class="list-inline-item cited-by__entry__author">Grace Lin, </li><li class="list-inline-item cited-by__entry__author">Ahmad Masri, </li><li class="list-inline-item cited-by__entry__author">Mathew S. Maurer, </li><li class="list-inline-item cited-by__entry__author">Clemens Mittmann, </li><li class="list-inline-item cited-by__entry__author">Krishna Prasad, </li><li class="list-inline-item cited-by__entry__author">Cristina C. Quarta, </li><li class="list-inline-item cited-by__entry__author">Jean-Michel Race, </li><li class="list-inline-item cited-by__entry__author">Joseph G. Rajendran, </li><li class="list-inline-item cited-by__entry__author">Frederick L. Ruberg, </li><li class="list-inline-item cited-by__entry__author">Vandana Sachdev, </li><li class="list-inline-item cited-by__entry__author">Vaishali Sanchorawala, </li><li class="list-inline-item cited-by__entry__author">James Signorovitch, </li><li class="list-inline-item cited-by__entry__author">Christophe Sirac, </li><li class="list-inline-item cited-by__entry__author">Prem Soman, </li><li class="list-inline-item cited-by__entry__author">Jens Sorensen, </li><li class="list-inline-item cited-by__entry__author">Brett W. Sperry, </li><li class="list-inline-item cited-by__entry__author">Andrew W. Stephens, </li><li class="list-inline-item cited-by__entry__author">Norman L. Stockbridge, </li><li class="list-inline-item cited-by__entry__author">John Vest, </li><li class="list-inline-item cited-by__entry__author">Jonathan S. Wall, </li><li class="list-inline-item cited-by__entry__author">Ashutosh Wechalekar, </li><li class="list-inline-item cited-by__entry__author">Cynthia Welsh, </li><li class="list-inline-item cited-by__entry__author">Isabelle Lousada, </li></ul><span class="cited-by__entry__title">Development of Imaging Endpoints for&nbsp;Clinical Trials in AL and ATTR&nbsp;Amyloidosis, </span><span class="cited-by__entry__series-title">JACC: Cardiovascular Imaging, </span><span class="cited-by__entry__volume"><strong>18</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(602-617), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jcmg.2024.11.003" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jcmg.2024.11.003</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jcmg.2024.11.003" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Dr Sumeet Mirgh, </li><li class="list-inline-item cited-by__entry__author">Dr Uday Yanamandra, </li><li class="list-inline-item cited-by__entry__author">Dr Ganesh K Vishvanathan, </li><li class="list-inline-item cited-by__entry__author">Dr Sadashivudu Gundeti, </li><li class="list-inline-item cited-by__entry__author">Dr Navin Khattry, </li><li class="list-inline-item cited-by__entry__author">Dr M Joseph John, </li><li class="list-inline-item cited-by__entry__author">Dr Pankaj Malhotra, </li><li class="list-inline-item cited-by__entry__author">Dr Hari Menon, </li><li class="list-inline-item cited-by__entry__author">Dr Brig Satyaranjan Das, </li><li class="list-inline-item cited-by__entry__author">Dr Reena Nair, </li><li class="list-inline-item cited-by__entry__author">Lt Gen Dr Velu Nair, </li><li class="list-inline-item cited-by__entry__author">Dr Tapan Saikia, </li><li class="list-inline-item cited-by__entry__author">Dr Shaji K Kumar, </li></ul><span class="cited-by__entry__title">Clinical Perspectives on Amyloidosis in India: A Systematic Literature Review, </span><span class="cited-by__entry__series-title">Clinical Lymphoma Myeloma and Leukemia, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.clml.2025.05.014" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.clml.2025.05.014</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.clml.2025.05.014" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2028631%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-1" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2028631" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2028631" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2028631.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f0"><figure class="graphic"><a class="open-in-viewer" href="#f0" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028631_f0.jpg"><img src="/cms/10.1056/NEJMoa2028631/asset/6cb2c449-c7e6-4786-a365-d1cd1f17b89b/assets/images/large/nejmoa2028631_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f0"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028631_f0.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028631_f1.jpg"><img src="/cms/10.1056/NEJMoa2028631/asset/89c65f21-b9b1-49ce-b821-7df431674e5e/assets/images/large/nejmoa2028631_f1.jpg" height="2910" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Prespecified Subgroup Analysis of Hematologic Complete Response.</div><div class="notes"><div role="doc-footnote">Shown are the results of an analysis of hematologic complete response in prespecified subgroups in the intention-to-treat population, which included all the patients who underwent randomization. Patients in the daratumumab group were assigned to receive treatment with daratumumab, bortezomib, cyclophosphamide, and dexamethasone; patients in the control group were assigned to receive treatment with bortezomib, cyclophosphamide, and dexamethasone. Race was reported by the patient. Cardiac stage is based on the combination of N-terminal pro–B-type natriuretic peptide and high-sensitivity cardiac troponin T. Patients who had a cardiac stage of IIIB at screening were excluded from the trial according to the protocol. The category of cardiac stage IIIA or IIIB includes patients who had a cardiac stage of IIIA at screening but progressed to stage IIIB at cycle 1, day 1. Renal stage is based on the combination of estimated glomerular filtration rate and urinary protein excretion. Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with 0 indicating no symptoms and higher scores indicating increasing disability. High cytogenetic risk was defined by fluorescence in situ hybridization (FISH) testing as a t(4;14) mutation, t(14;16) mutation, or 17p deletion or by karyotype testing as a t(4;14) mutation or 17p deletion. AL denotes immunoglobulin light chain, and NE could not be estimated.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028631_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028631_f2.jpg"><img src="/cms/10.1056/NEJMoa2028631/asset/ca494efe-7239-4761-91c1-451404ae1791/assets/images/large/nejmoa2028631_f2.jpg" height="1958" width="2231" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Kaplan–Meier Estimates of Survival Free from Major Organ Deterioration or Hematologic Progression.</div><div class="notes"><div role="doc-footnote">Shown are the results of the Kaplan–Meier estimates of survival from major organ deterioration or hematologic progression among patients in the intention-to-treat population. Major organ deterioration was defined as end-stage cardiac or renal failure.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028631_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2028631/asset/cd975afe-f8f7-47ce-ae6b-36d20b85e91e/assets/images/large/nejmoa2028631_t1.jpg" height="3318" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Daratumumab Group<br>(N=195)</th><th class="txxr-borders">Control Group<br>(N=193)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading">Age</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Median (range) — yr</td><td class="xxxx-borders">62 (34–87)</td><td class="xxxr-borders">64 (35–86)</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Distribution — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">&lt;65 yr</td><td class="xxxx-borders">108 (55.4)</td><td class="xxxr-borders">97 (50.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">≥65 yr</td><td class="xxxx-borders shading">87 (44.6)</td><td class="xxxr-borders shading">96 (49.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Sex — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Male</td><td class="xxxx-borders shading">108 (55.4)</td><td class="xxxr-borders shading">117 (60.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Female</td><td class="xxxx-borders">87 (44.6)</td><td class="xxxr-borders">76 (39.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">ECOG performance-status score — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">0</td><td class="xxxx-borders">90 (46.2)</td><td class="xxxr-borders">71 (36.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">86 (44.1)</td><td class="xxxr-borders shading">106 (54.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">2</td><td class="xxxx-borders">19 (9.7)</td><td class="xxxr-borders">16 (8.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">AL isotype — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Lambda</td><td class="xxxx-borders">158 (81.0)</td><td class="xxxr-borders">149 (77.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Kappa</td><td class="xxxx-borders shading">37 (19.0)</td><td class="xxxr-borders shading">44 (22.8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">dFLC</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Median (range) — mg/liter</td><td class="xxxx-borders shading">200 (2–4749)</td><td class="xxxr-borders shading">186 (1–9983)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">&lt;50 mg/liter — no. (%)</td><td class="xxxx-borders">23 (11.8)</td><td class="xxxr-borders">13 (6.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">&lt;20 mg/liter — no. (%)</td><td class="xxxx-borders shading">10 (5.1)</td><td class="xxxr-borders shading">5 (2.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Median time since amyloidosis diagnosis (range) — days</td><td class="xxxx-borders">48 (8–1611)</td><td class="xxxr-borders">43 (5–1102)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Involved organs</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Median (range)</td><td class="xxxx-borders">2 (1–5)</td><td class="xxxr-borders">2 (1–6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Distribution — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Heart</td><td class="xxxx-borders">140 (71.8)</td><td class="xxxr-borders">137 (71.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Kidney</td><td class="xxxx-borders shading">115 (59.0)</td><td class="xxxr-borders shading">114 (59.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Liver</td><td class="xxxx-borders">15 (7.7)</td><td class="xxxr-borders">16 (8.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Other<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">127 (65.1)</td><td class="xxxr-borders shading">124 (64.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Cardiac stage — no. (%)<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">I</td><td class="xxxx-borders shading">47 (24.1)</td><td class="xxxr-borders shading">43 (22.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">II</td><td class="xxxx-borders">76 (39.0)</td><td class="xxxr-borders">80 (41.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">IIIA</td><td class="xxxx-borders shading">70 (35.9)</td><td class="xxxr-borders shading">64 (33.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">IIIB<a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">2 (1.0)</td><td class="xxxr-borders">6 (3.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Renal stage — no./total no. (%)<a href="#core-t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">I</td><td class="xxxx-borders">107/193 (55.4)</td><td class="xxxr-borders">101/193 (52.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">II</td><td class="xxxx-borders shading">67/193 (34.7)</td><td class="xxxr-borders shading">74/193 (38.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">III</td><td class="xxxx-borders">19/193 (9.8)</td><td class="xxxr-borders">18/193 (9.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Creatinine clearance — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">&lt;60 ml/min</td><td class="xxxx-borders">69 (35.4)</td><td class="xxxr-borders">62 (32.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">≥60 ml/min</td><td class="xxxx-borders shading">126 (64.6)</td><td class="xxxr-borders shading">131 (67.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Residence in a country that typically offers transplantation for patients with AL amyloidosis — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Yes</td><td class="xxxx-borders shading">147 (75.4)</td><td class="xxxr-borders shading">146 (75.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">No</td><td class="xxxx-borders">48 (24.6)</td><td class="xxxr-borders">47 (24.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Median NT-proBNP level (range) — ng/liter</td><td class="xxxx-borders shading">1388.6 (51–10,182)</td><td class="xxxr-borders shading">1746.0 (51–12,950)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging03" data-xml-align="left">Median estimated GFR (range) — ml/min/1.73 m<sup>2</sup></td><td class="xbxx-borders">77.8 (21–126)</td><td class="xbxr-borders">76.2 (20–121)</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t1.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t1.jpg"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">The intention-to-treat population included all the patients who underwent randomization. AL denotes immunoglobulin light chain, dFLC the difference between involved and uninvolved free light-chain levels, GFR glomerular filtration rate, and NT-proBNP N-terminal pro–B-type natriuretic peptide.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with 0 indicating no symptoms and higher scores indicating increasing disability.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Data are based on immunofixation or light-chain measurement.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Other includes gastrointestinal tract, lung, peripheral nervous system, autonomic nervous system, and soft tissue.</div></div></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t1.jpg"><div class="label">¶</div></a><div id="core-t1fn5" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t1.jpg">Cardiac stage was classified in accordance with the European modification of the staging system of the Mayo Clinic.<sup></sup></a><a href="#core-r29" role="doc-biblioref" data-xml-rid="r29" id="core-body-ref-r29" href-manipulated="true" aria-label="Reference 29" data-to-manipulate="false">29</a> Cardiac stage was based on two biomarker risk factors — NT-proBNP and high-sensitivity cardiac troponin T — that were assessed at a central laboratory.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">All the patients had a cardiac stage of I, II, or IIIA at screening; however, some converted to stage IIIB at cycle 1, day 1 (results determined by the central laboratory were made available only after cycle 1, day 1).</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t1fn7" role="paragraph" data-to-manipulate="true">Renal stage is based on the combination of estimated GFR and urinary protein excretion.<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27" id="core-body-ref-r27-2" href-manipulated="true" aria-label="Reference 27" data-to-manipulate="false">27</a></sup></div></div></div></figcaption><figcaption><div class="caption">Demographic and Disease Characteristics of the Patients at Baseline (Intention-to-Treat Population).<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2028631/asset/cdaeace3-bf24-4d71-bd53-66ebaf9cdde9/assets/images/large/nejmoa2028631_t2.jpg" height="2327" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Response</th><th class="txxx-borders">Daratumumab Group <br>(N=195)</th><th class="txxx-borders">Control Group <br>(N=193)</th><th class="txxr-borders">P Value<a href="#core-t2fn2" role="doc-noteref">†</a></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading">Hematologic response</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Any response — no. of patients</td><td class="xxxx-borders">179</td><td class="xxxx-borders">148</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders shading">91.8 (87.0–95.2)</td><td class="xxxx-borders shading">76.7 (70.1–82.5)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Complete response — no. of patients<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">104<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">35<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders shading">53.3 (46.1–60.5)</td><td class="xxxx-borders shading">18.1 (13.0–24.3)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Very good partial response or better — no. (%)</td><td class="xxxx-borders">153 (78.5)</td><td class="xxxx-borders">95 (49.2)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Very good partial response — no. (%)</td><td class="xxxx-borders shading">49 (25.1)</td><td class="xxxx-borders shading">60 (31.1)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Partial response — no. (%)</td><td class="xxxx-borders">26 (13.3)</td><td class="xxxx-borders">53 (27.5)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">No response — no. (%)</td><td class="xxxx-borders shading">8 (4.1)</td><td class="xxxx-borders shading">38 (19.7)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Progressive disease — no. (%)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Response could not be evaluated — no. (%)</td><td class="xxxx-borders shading">8 (4.1)</td><td class="xxxx-borders shading">7 (3.6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Involved free light-chain level ≤20 mg/liter — no./total no. (%)<a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">136/193 (70.5)</td><td class="xxxx-borders">39/193 (20.2)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">dFLC &lt;10 mg/liter — no./total no. (%)<a href="#core-t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">119/188 (63.3)</td><td class="xxxx-borders shading">56/190 (29.5)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Cardiac response at 6 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">No. of patients who could be evaluated<a href="#core-t2fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">118</td><td class="xxxx-borders shading">117</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Percent with a response (95% CI)</td><td class="xxxx-borders">41.5 (32.5–51.0)</td><td class="xxxx-borders">22.2 (15.1–30.8)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Renal response at 6 mo</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">No. of patients who could be evaluated<a href="#core-t2fn8" role="doc-noteref">††</a></td><td class="xxxx-borders">117</td><td class="xxxx-borders">113</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13 shading" data-xml-align="left">Percent with a response (95% CI)</td><td class="xbxx-borders shading">53.0 (43.5–62.3)</td><td class="xbxx-borders shading">23.9 (16.4–32.8)</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t2.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t2.jpg"></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t2.jpg"><div class="label">*</div></a><div id="core-t2fn1" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t2.jpg">Hematologic response was assessed centrally in the intention-to-treat population. Organ response in patients with measurable organ involvement was assessed by an independent review committee whose members were unaware of the trial-group assignments, according to previously validated criteria that are outlined in the protocol.<sup></sup></a><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26 r27" id="core-body-ref-r27-3" href-manipulated="true" data-to-manipulate="false">26,27</a> CI denotes confidence interval.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">The P value was calculated with the use of the Cochran–Mantel–Haenszel chi-square test.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">Complete response was based on consensus criteria with clarifications as specified in the trial protocol that required confirmation by the independent review committee. Complete response was defined as negative immunofixation and normalization of the free light-chain ratio without confirmation,<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="core-body-ref-r26-3" href-manipulated="true" aria-label="Reference 26" data-to-manipulate="false">26</a></sup> a reduction in the absolute involved free light-chain level to 20 mg or less per liter,<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="core-body-ref-r25-2" href-manipulated="true" aria-label="Reference 25" data-to-manipulate="false">25</a></sup> and a reduction in the dFLC to less than 10 mg per liter.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="core-body-ref-r5-3" href-manipulated="true" aria-label="Reference 5" data-to-manipulate="false">5</a></sup></div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">Of the 104 patients who had a hematologic complete response in the daratumumab group, 4 patients died while in complete response and no patients with a complete response had a relapse. Of the 35 patients who had a hematologic complete response in the control group, 2 patients died while in complete response and 2 patients had a relapse after a complete response.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">Excluded are 2 patients with an involved free light-chain level of 20 mg or less per liter at baseline (both in the daratumumab group).</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t2fn6" role="paragraph" data-to-manipulate="true">Excluded are 10 patients with a dFLC of less than 10 mg per liter at baseline (7 in the daratumumab group and 3 in the control group).</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t2fn7" role="paragraph" data-to-manipulate="true">Patients who could be evaluated for cardiac response were defined as those with a baseline NT-proBNP value of 650 ng or more per liter or a baseline New York Heart Association (NYHA) class of III or IV. In addition, patients must have received at least one administration of trial treatment and have had at least one postbaseline NT-proBNP measurement (if the baseline NT-proBNP was ≥650 ng per liter) or NYHA function evaluation (if the baseline NYHA class was III or IV).</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="core-t2fn8" role="paragraph" data-to-manipulate="true">Patients who could be evaluated for renal response were defined as those with a baseline urinary protein excretion of more than 0.5 g per day. In addition, patients must have received at least one administration of trial treatment and had at least one postbaseline measurement of urinary protein excretion.</div></div></div></figcaption><figcaption><div class="caption">Summary of Overall Confirmed Hematologic Responses and Cardiac and Renal Responses at 6 Months.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2028631/asset/3ecd9eea-2f02-4059-bd05-75149f3fcceb/assets/images/large/nejmoa2028631_t3.jpg" height="1307" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="2"><span>Daratumumab Group<br>(N=193)</span></th><th class="txxr-borders" colspan="2"><span>Control Group<br>(N=188)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 3 or 4</th><th class="xxxx-borders">Any Grade</th><th class="xxxr-borders">Grade 3 or 4</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="4"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Diarrhea</td><td class="xxxx-borders shading">69 (35.8)</td><td class="xxxx-borders shading">11 (5.7)</td><td class="xxxx-borders shading">57 (30.3)</td><td class="xxxr-borders shading">7 (3.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Peripheral edema</td><td class="xxxx-borders">69 (35.8)</td><td class="xxxx-borders">6 (3.1)</td><td class="xxxx-borders">68 (36.2)</td><td class="xxxr-borders">11 (5.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">66 (34.2)</td><td class="xxxx-borders shading">3 (1.6)</td><td class="xxxx-borders shading">54 (28.7)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Peripheral sensory neuropathy</td><td class="xxxx-borders">60 (31.1)</td><td class="xxxx-borders">5 (2.6)</td><td class="xxxx-borders">37 (19.7)</td><td class="xxxr-borders">4 (2.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Fatigue</td><td class="xxxx-borders shading">52 (26.9)</td><td class="xxxx-borders shading">8 (4.1)</td><td class="xxxx-borders shading">53 (28.2)</td><td class="xxxr-borders shading">6 (3.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Nausea</td><td class="xxxx-borders">52 (26.9)</td><td class="xxxx-borders">3 (1.6)</td><td class="xxxx-borders">52 (27.7)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders shading">50 (25.9)</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">21 (11.2)</td><td class="xxxr-borders shading">1 (0.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Lymphopenia</td><td class="xxxx-borders">36 (18.7)</td><td class="xxxx-borders">25 (13.0)</td><td class="xxxx-borders">28 (14.9)</td><td class="xxxr-borders">19 (10.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hypokalemia</td><td class="xxxx-borders shading">24 (12.4)</td><td class="xxxx-borders shading">3 (1.6)</td><td class="xxxx-borders shading">28 (14.9)</td><td class="xxxr-borders shading">10 (5.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Neutropenia</td><td class="xxxx-borders">21 (10.9)</td><td class="xxxx-borders">10 (5.2)</td><td class="xxxx-borders">12 (6.4)</td><td class="xxxr-borders">5 (2.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Pneumonia</td><td class="xxxx-borders shading">21 (10.9)</td><td class="xxxx-borders shading">15 (7.8)</td><td class="xxxx-borders shading">12 (6.4)</td><td class="xxxr-borders shading">8 (4.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Syncope</td><td class="xxxx-borders">14 (7.3)</td><td class="xxxx-borders">10 (5.2)</td><td class="xxxx-borders">12 (6.4)</td><td class="xxxr-borders">12 (6.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01 shading" data-xml-align="left">Cardiac failure<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xbxx-borders shading">18 (9.3)</td><td class="xbxx-borders shading">12 (6.2)</td><td class="xbxx-borders shading">14 (7.4)</td><td class="xbxr-borders shading">9 (4.8)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">The safety population included patients who received at least one administration of trial treatment. Shown are adverse events of any grade that occurred in more than 25% of the patients in either group and grade 3 or 4 events that occurred in at least 5% of the patients in either group.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">This category includes overall and congestive cardiac failure.</div></div></div></figcaption></a><figcaption><div class="caption">Most Common Adverse Events during Treatment (Safety Population).<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2028631_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2028631</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. <em>Nat Rev Dis Primers</em> 2018;4:38-38.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41572-018-0034-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30361521/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000448497700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Systemic+immunoglobulin+light+chain+amyloidosis.&amp;publication_year=2018&amp;journal=Nat+Rev+Dis+Primers&amp;pages=38-38&amp;doi=10.1038%2Fs41572-018-0034-3&amp;pmid=30361521" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r1-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] most frequently to the heart and kidneys. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] leads to progressive disability and death. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Weiss BM, Hebreo J, Cordaro DV, et al. Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis. <em>J Clin Oncol</em> 2014;32:2699-2704.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2013.50.0892" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25024082/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000341562600007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Increased+serum+free+light+chains+precede+the+presentation+of+immunoglobulin+light+chain+amyloidosis.&amp;publication_year=2014&amp;journal=J+Clin+Oncol&amp;pages=2699-2704&amp;doi=10.1200%2FJCO.2013.50.0892&amp;pmid=25024082" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. <em>Blood</em> 2015;126:612-615.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2015-01-620302" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25987656/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000358871900012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+European+collaborative+study+of+cyclophosphamide%2C+bortezomib%2C+and+dexamethasone+in+upfront+treatment+of+systemic+AL+amyloidosis.&amp;publication_year=2015&amp;journal=Blood&amp;pages=612-615&amp;doi=10.1182%2Fblood-2015-01-620302&amp;pmid=25987656" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] leads to progressive disability and death. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] is the most commonly used regimen. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] of the Mayo Clinic Cardiac Staging System), </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] complete response of approximately 24%. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. <em>J Clin Oncol</em> 2020;38:3252-3260.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.20.01285" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32730181/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000587963400004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bortezomib%2C+melphalan%2C+and+dexamethasone+for+light-chain+amyloidosis.&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;pages=3252-3260&amp;doi=10.1200%2FJCO.20.01285&amp;pmid=32730181" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] is the most commonly used regimen. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] complete response of approximately 24%. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Manwani R, Cohen O, Sharpley F, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. <em>Blood</em> 2019;134:2271-2280.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019000834" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31578202/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000506630200008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+prospective+observational+study+of+915+patients+with+systemic+AL+amyloidosis+treated+with+upfront+bortezomib.&amp;publication_year=2019&amp;journal=Blood&amp;pages=2271-2280&amp;doi=10.1182%2Fblood.2019000834&amp;pmid=31578202" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] is the most commonly used regimen. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] required to determine a complete response. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t2" role="menuitem" data-target="#fv-body-ref-r5-3"><i aria-hidden="true" class="icon-return"></i><span>c [...] in the dFLC to less than 10 mg per liter. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r32" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] levels to less than 10 mg per liter. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] complete response of approximately 24%. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Muchtar E, Gertz MA, Kumar SK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <em>Blood</em> 2017;129:2111-2119.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2016-11-751628" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28126928/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000399008200015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Improved+outcomes+for+newly+diagnosed+AL+amyloidosis+between+2000+and+2014%3A+cracking+the+glass+ceiling+of+early+death.&amp;publication_year=2017&amp;journal=Blood&amp;pages=2111-2119&amp;doi=10.1182%2Fblood-2016-11-751628&amp;pmid=28126928" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">de Weers M, Tai Y-T, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. <em>J Immunol</em> 2011;186:1840-1848.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.1003032" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21187443/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000286381200064" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Daratumumab%2C+a+novel+therapeutic+human+CD38+monoclonal+antibody%2C+induces+killing+of+multiple+myeloma+and+other+hematological+tumors.&amp;publication_year=2011&amp;journal=J+Immunol&amp;pages=1840-1848&amp;doi=10.4049%2Fjimmunol.1003032&amp;pmid=21187443" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Overdijk MB, Jansen JHM, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor-mediated cross-linking. <em>J Immunol</em> 2016;197:807-813.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.1501351" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27316683/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000380338600014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+therapeutic+CD38+monoclonal+antibody+daratumumab+induces+programmed+cell+death+via+Fc%CE%B3+receptor-mediated+cross-linking.&amp;publication_year=2016&amp;journal=J+Immunol&amp;pages=807-813&amp;doi=10.4049%2Fjimmunol.1501351&amp;pmid=27316683" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Overdijk MB, Verploegen S, Bögels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. <em>MAbs</em> 2015;7:311-321.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/19420862.2015.1007813" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25760767/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000351244000004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antibody-mediated+phagocytosis+contributes+to+the+anti-tumor+activity+of+the+therapeutic+antibody+daratumumab+in+lymphoma+and+multiple+myeloma.&amp;publication_year=2015&amp;journal=MAbs&amp;pages=311-321&amp;doi=10.1080%2F19420862.2015.1007813&amp;pmid=25760767" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Lammerts van Bueren J, Jakobs D, Kaldenhoven N, et al. Direct <i>in vitro</i> comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. <em>Blood</em> 2014;124:3474-3474 (<a href="https://ashpublications.org/blood/article/124/21/3474/97703/Direct-in-Vitro-Comparison-of-Daratumumab-with" target="_blank">https://ashpublications.org/blood/article/124/21/3474/97703/Direct-in-Vitro-Comparison-of-Daratumumab-with</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.V124.21.3474.3474" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000349242706125" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Direct+in+vitro+comparison+of+daratumumab+with+surrogate+analogs+of+CD38+antibodies+MOR03087%2C+SAR650984+and+Ab79.&amp;publication_year=2014&amp;journal=Blood&amp;pages=3474-3474&amp;doi=10.1182%2Fblood.V124.21.3474.3474" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38<sup>+</sup> immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. <em>Blood</em> 2016;128:384-394.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2015-12-687749" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27222480/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000384078200012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Daratumumab+depletes+CD38%2B+immune+regulatory+cells%2C+promotes+T-cell+expansion%2C+and+skews+T-cell+repertoire+in+multiple+myeloma.&amp;publication_year=2016&amp;journal=Blood&amp;pages=384-394&amp;doi=10.1182%2Fblood-2015-12-687749&amp;pmid=27222480" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Adams HC III, Stevenaert F, Krejcik J, et al. High-parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action. <em>Cytometry A</em> 2019;95:279-289.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/cyto.a.23693" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30536810/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000460979500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=High-parameter+mass+cytometry+evaluation+of+relapsed%2Frefractory+multiple+myeloma+patients+treated+with+daratumumab+demonstrates+immune+modulation+as+a+novel+mechanism+of+action.&amp;publication_year=2019&amp;journal=Cytometry+A&amp;pages=279-289&amp;doi=10.1002%2Fcyto.a.23693&amp;pmid=30536810" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Casneuf T, Adams HC III, van de Donk NWCJ, et al. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. <em>Leukemia</em> 2021;35:573-584.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41375-020-0855-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32457357/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000559642100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Deep+immune+profiling+of+patients+treated+with+lenalidomide+and+dexamethasone+with+or+without+daratumumab.&amp;publication_year=2021&amp;journal=Leukemia&amp;pages=573-584&amp;doi=10.1038%2Fs41375-020-0855-4&amp;pmid=32457357" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content"><em>Darzalex (daratumumab)</em>. Horsham, PA: Janssen Biotech, August 2020 (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Darzalex+%28daratumumab%29&amp;publication_year=2020" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] regimens for multiple myeloma. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] adverse events and infections was observed. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Kaufman GP, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. <em>Blood</em> 2017;130:900-902.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2017-01-763599" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28615223/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000407779500011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Daratumumab+yields+rapid+and+deep+hematologic+responses+in+patients+with+heavily+pretreated+AL+amyloidosis.&amp;publication_year=2017&amp;journal=Blood&amp;pages=900-902&amp;doi=10.1182%2Fblood-2017-01-763599&amp;pmid=28615223" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Khouri J, Kin A, Thapa B, et al. Daratumumab proves safe and highly effective in AL amyloidosis. <em>Br J Haematol</em> 2019;185:342-344.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.15455" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29938774/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000467975200021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Daratumumab+proves+safe+and+highly+effective+in+AL+amyloidosis.&amp;publication_year=2019&amp;journal=Br+J+Haematol&amp;pages=342-344&amp;doi=10.1111%2Fbjh.15455&amp;pmid=29938774" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Abeykoon JP, Zanwar S, Dispenzieri A, et al. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <em>Leukemia</em> 2019;33:531-536.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41375-018-0262-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30267007/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457857300026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Daratumumab-based+therapy+in+patients+with+heavily-pretreated+AL+amyloidosis.&amp;publication_year=2019&amp;journal=Leukemia&amp;pages=531-536&amp;doi=10.1038%2Fs41375-018-0262-2&amp;pmid=30267007" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Roussel M, Merlini G, Chevret S, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. <em>Blood</em> 2020;135:1531-1540.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019004369" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32108228/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000534368300006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+prospective+phase+2+trial+of+daratumumab+in+patients+with+previously+treated+systemic+light-chain+amyloidosis.&amp;publication_year=2020&amp;journal=Blood&amp;pages=1531-1540&amp;doi=10.1182%2Fblood.2019004369&amp;pmid=32108228" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Sanchorawala V, Sarosiek S, Schulman A, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. <em>Blood</em> 2020;135:1541-1547.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019004436" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31978210/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000534368300007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety%2C+tolerability%2C+and+response+rates+of+daratumumab+in+relapsed+AL+amyloidosis%3A+results+of+a+phase+2+study.&amp;publication_year=2020&amp;journal=Blood&amp;pages=1541-1547&amp;doi=10.1182%2Fblood.2019004436&amp;pmid=31978210" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Kimmich CR, Terzer T, Benner A, et al. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. <em>Blood</em> 2020;135:1517-1530.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019003633" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32107537/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000534368300005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Daratumumab+for+systemic+AL+amyloidosis%3A+prognostic+factors+and+adverse+outcome+with+nephrotic-range+albuminuria.&amp;publication_year=2020&amp;journal=Blood&amp;pages=1517-1530&amp;doi=10.1182%2Fblood.2019003633&amp;pmid=32107537" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Milani P, Fazio F, Basset M, et al. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate. <em>Am J Hematol</em> 2020;95:900-905.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ajh.25828" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32282971/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000529618900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=High+rate+of+profound+clonal+and+renal+responses+with+daratumumab+treatment+in+heavily+pre-treated+patients+with+light+chain+%28AL%29+amyloidosis+and+high+bone+marrow+plasma+cell+infiltrate.&amp;publication_year=2020&amp;journal=Am+J+Hematol&amp;pages=900-905&amp;doi=10.1002%2Fajh.25828&amp;pmid=32282971" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. <em>Blood</em> 2020;136:71-80.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2019004460" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32244252/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000550379200011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Daratumumab+plus+CyBorD+for+patients+with+newly+diagnosed+AL+amyloidosis%3A+safety+run-in+results+of+ANDROMEDA.&amp;publication_year=2020&amp;journal=Blood&amp;pages=71-80&amp;doi=10.1182%2Fblood.2019004460&amp;pmid=32244252" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <em>Lancet Oncol</em> 2014;15(12):e538-e548.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(14)70442-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25439696/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000344546400022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=International+Myeloma+Working+Group+updated+criteria+for+the+diagnosis+of+multiple+myeloma.&amp;publication_year=2014&amp;journal=Lancet+Oncol&amp;pages=e538-e548&amp;doi=10.1016%2FS1470-2045%2814%2970442-5&amp;pmid=25439696" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Sidana S, Dispenzieri A, Murray DL, et al. Revisiting complete response in light chain amyloidosis. <em>Leukemia</em> 2020;34:1472-1475.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41375-019-0664-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31772296/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000529704000026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Revisiting+complete+response+in+light+chain+amyloidosis.&amp;publication_year=2020&amp;journal=Leukemia&amp;pages=1472-1475&amp;doi=10.1038%2Fs41375-019-0664-9&amp;pmid=31772296" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Muchtar E, Dispenzieri A, Leung N, et al. Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <em>Leukemia</em> 2019;33:527-531.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r25-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41375-018-0258-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30258095/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457857300025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Optimizing+deep+response+assessment+for+AL+amyloidosis+using+involved+free+light+chain+level+at+end+of+therapy%3A+failure+of+the+serum+free+light+chain+ratio.&amp;publication_year=2019&amp;journal=Leukemia&amp;pages=527-531&amp;doi=10.1038%2Fs41375-018-0258-y&amp;pmid=30258095" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r25-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r25-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] required to determine a complete response. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t2" role="menuitem" data-target="#fv-body-ref-r25-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] level to 20 mg or less per liter, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r31" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] level to 20 mg or less per liter, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. <em>J Clin Oncol</em> 2012;30:4541-4549.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r26-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2011.37.7614" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23091105/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000312815000021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=New+criteria+for+response+to+treatment+in+immunoglobulin+light+chain+amyloidosis+based+on+free+light+chain+measurement+and+cardiac+biomarkers%3A+impact+on+survival+outcomes.&amp;publication_year=2012&amp;journal=J+Clin+Oncol&amp;pages=4541-4549&amp;doi=10.1200%2FJCO.2011.37.7614&amp;pmid=23091105" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r26-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r27-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] weighting method), organ response, </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t2" role="menuitem" data-target="#fv-body-ref-r26-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] criteria that are outlined in the protocol. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t2" role="menuitem" data-target="#fv-body-ref-r26-3"><i aria-hidden="true" class="icon-return"></i><span>c [...] light-chain ratio without confirmation, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] Society of Amyloidosis) (Table S6), </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] complete response of approximately 24%. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. <em>Blood</em> 2014;124:2325-2332.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r27-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2014-04-570010" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25115890/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000347454400009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+staging+system+for+renal+outcome+and+early+markers+of+renal+response+to+chemotherapy+in+AL+amyloidosis.&amp;publication_year=2014&amp;journal=Blood&amp;pages=2325-2332&amp;doi=10.1182%2Fblood-2014-04-570010&amp;pmid=25115890" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r27-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r27-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] weighting method), organ response, </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t1" role="menuitem" data-target="#fv-body-ref-r27-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] GFR and urinary protein excretion. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t2" role="menuitem" data-target="#fv-body-ref-r27-3"><i aria-hidden="true" class="icon-return"></i><span>c [...] criteria that are outlined in the protocol. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Tang DI, Geller NL. Closed testing procedures for group sequential clinical trials with multiple endpoints. <em>Biometrics</em> 1999;55:1188-1192.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.0006-341X.1999.01188.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11315066/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000084218000027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Closed+testing+procedures+for+group+sequential+clinical+trials+with+multiple+endpoints.&amp;publication_year=1999&amp;journal=Biometrics&amp;pages=1188-1192&amp;doi=10.1111%2Fj.0006-341X.1999.01188.x&amp;pmid=11315066" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? <em>Blood</em> 2016;128:159-168.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2016-01-629790" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27053535/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000383830000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=What+is+new+in+diagnosis+and+management+of+light+chain+amyloidosis%3F&amp;publication_year=2016&amp;journal=Blood&amp;pages=159-168&amp;doi=10.1182%2Fblood-2016-01-629790&amp;pmid=27053535" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Sarosiek S, Zheng L, Sloan JM, Quillen K, Brauneis D, Sanchorawala V. Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis. <em>Blood Cancer J</em> 2020;10:88-88.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41408-020-00354-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32873776/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000569421400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparing+measures+of+hematologic+response+after+high-dose+melphalan+and+stem+cell+transplantation+in+AL+amyloidosis.&amp;publication_year=2020&amp;journal=Blood+Cancer+J&amp;pages=88-88&amp;doi=10.1038%2Fs41408-020-00354-7&amp;pmid=32873776" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Milani P, Basset M, Nuvolone M, et al. Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy. <em>Blood Cancer J</em> 2020;10:90-90.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41408-020-00355-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32873771/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000569421400003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Indicators+of+profound+hematologic+response+in+AL+amyloidosis%3A+complete+response+remains+the+goal+of+therapy.&amp;publication_year=2020&amp;journal=Blood+Cancer+J&amp;pages=90-90&amp;doi=10.1038%2Fs41408-020-00355-6&amp;pmid=32873771" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Muchtar E, Gertz MA, Lacy MQ, et al. Refining amyloid complete hematological response: quantitative serum free light chains superior to ratio. <em>Am J Hematol</em> 2020;95:1280-1287.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ajh.25940" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32681737/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000561955500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Refining+amyloid+complete+hematological+response%3A+quantitative+serum+free+light+chains+superior+to+ratio.&amp;publication_year=2020&amp;journal=Am+J+Hematol&amp;pages=1280-1287&amp;doi=10.1002%2Fajh.25940&amp;pmid=32681737" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="core-r33" class="citations"><div class="citation"><div class="citation-content">Palladini G, Schönland SO, Sanchorawala V, et al. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. <em>Amyloid</em> 2021;28:1-2.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/13506129.2020.1868810" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33410355/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000605715300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clarification+on+the+definition+of+complete+haematologic+response+in+light-chain+%28AL%29+amyloidosis.&amp;publication_year=2021&amp;journal=Amyloid&amp;pages=1-2&amp;doi=10.1080%2F13506129.2020.1868810&amp;pmid=33410355" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="core-r34" class="citations"><div class="citation"><div class="citation-content">Kaufman GP, Dispenzieri A, Gertz MA, et al. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. <em>Am J Hematol</em> 2015;90:181-186.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ajh.23898" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25388651/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000349889300009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Kinetics+of+organ+response+and+survival+following+normalization+of+the+serum+free+light+chain+ratio+in+AL+amyloidosis.&amp;publication_year=2015&amp;journal=Am+J+Hematol&amp;pages=181-186&amp;doi=10.1002%2Fajh.23898&amp;pmid=25388651" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="core-r35" class="citations"><div class="citation"><div class="citation-content">Muchtar E, Dispenzieri A, Leung N, et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <em>Leukemia</em> 2018;32:2240-2249.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41375-018-0060-x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29581546/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000446171800013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Depth+of+organ+response+in+AL+amyloidosis+is+associated+with+improved+survival%3A+grading+the+organ+response+criteria.&amp;publication_year=2018&amp;journal=Leukemia&amp;pages=2240-2249&amp;doi=10.1038%2Fs41375-018-0060-x&amp;pmid=29581546" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="core-r36" class="citations"><div class="citation"><div class="citation-content">Mateos M-V, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. <em>Lancet Haematol</em> 2020;7(5):e370-e380.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2352-3026(20)30070-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32213342/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000530901900013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Subcutaneous+versus+intravenous+daratumumab+in+patients+with+relapsed+or+refractory+multiple+myeloma+%28COLUMBA%29%3A+a+multicentre%2C+open-label%2C+non-inferiority%2C+randomised%2C+phase+3+trial.&amp;publication_year=2020&amp;journal=Lancet+Haematol&amp;pages=e370-e380&amp;doi=10.1016%2FS2352-3026%2820%2930070-3&amp;pmid=32213342" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/549081/bc-be-laborist/?query=fjwp&amp;rid=3059">BC/BE Laborist</a></div></div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Rheumatology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/720346/rheumatologists-needed-for-multiple-locations-in-new-york-/?query=fjwp&amp;rid=3059">Rheumatologists Needed for Multiple Locations in New York </a></div></div><div class="nejm-widget_item"><div><span> Cleveland, Ohio</span></div><div><span>Surgery, General</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/877997/vascular-surgeons-cleveland-clinic-health-system-west-side/?query=fjwf&amp;rid=2201">Vascular Surgeons Cleveland Clinic Health System West Side</a></div></div><div class="nejm-widget_item"><div><span> Oregon</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/881443/obgyn-oregon-mountains-near-coast-500k-proven-earning-robotics-onsite/?query=fjwf&amp;rid=5263">OBGYN | Oregon Mountains Near Coast | 500k+ Proven Earning | Robotics Onsite</a></div></div><div class="nejm-widget_item"><div><span> Manhasset, New York</span></div><div><span>Pulmonary Disease</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/858772/interventional-pulmonary-physician-north-shore-university-hosp-and-long-island-jewish-medical-center/?query=fjwp&amp;rid=3059">Interventional Pulmonary Physician North Shore University Hosp and Long Island Jewish Medical Center</a></div></div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Surgery, Orthopedic</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885284/orthopedic-total-joint-surgeons-nassau-county-ny/?query=fjwp&amp;rid=6262">Orthopedic Total Joint Surgeons - Nassau County, NY</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128720&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejmai%2Fregister%2Faifallpdf24%3Fpromo%3DOAFQF4NA%26query%3Dcm-rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Daifallpdf24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2028631&amp;pubId=41290435&amp;placeholderId=101337&amp;productId=1007" target="_blank"><img src="/sda/128720/NEJ-AI-Fall24-300x250---002.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d68a6c257f6224-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d68a6c257f6224-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d68a6c257f6224-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$362106140$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$362106140$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$362106140$--></div></div><div class="mlt-body"><!--?lit$362106140$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$362106140$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$362106140$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$362106140$-->Jan 25, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2312054?query=recirc_Semantic" target="_self">Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma</a></div><div class="mlt-article-authors"><!--?lit$362106140$-->P. Sonneveld and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$362106140$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$362106140$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$362106140$-->Aug 01, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2405090?query=recirc_Semantic" target="_self">Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma</a></div><div class="mlt-article-authors"><!--?lit$362106140$-->V. Hungria and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$362106140$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$362106140$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$362106140$-->Oct 10, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2410841?query=recirc_Semantic" target="_self">Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma</a></div><div class="mlt-article-authors"><!--?lit$362106140$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$362106140$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$362106140$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$362106140$-->May 08, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2409029?query=recirc_Semantic" target="_self">Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma</a></div><div class="mlt-article-authors"><!--?lit$362106140$-->M.A. Dimopoulos and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$362106140$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$362106140$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$362106140$-->Oct 31, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2400712?query=recirc_Semantic" target="_self">Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma</a></div><div class="mlt-article-authors"><!--?lit$362106140$-->T. Facon and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2028631?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2028631" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2028631.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2028631"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2032441" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMra2106545" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Cerebral Venous Thrombosis</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f0" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028631_f0.jpg"><img src="/cms/10.1056/NEJMoa2028631/asset/6cb2c449-c7e6-4786-a365-d1cd1f17b89b/assets/images/large/nejmoa2028631_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title"></div><div class="fv__item__description"><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028631_f1.jpg"><img src="/cms/10.1056/NEJMoa2028631/asset/89c65f21-b9b1-49ce-b821-7df431674e5e/assets/images/large/nejmoa2028631_f1.jpg" height="2910" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Prespecified Subgroup Analysis of Hematologic Complete Response.</div><div class="notes"><div role="doc-footnote">Shown are the results of an analysis of hematologic complete response in prespecified subgroups in the intention-to-treat population, which included all the patients who underwent randomization. Patients in the daratumumab group were assigned to receive treatment with daratumumab, bortezomib, cyclophosphamide, and dexamethasone; patients in the control group were assigned to receive treatment with bortezomib, cyclophosphamide, and dexamethasone. Race was reported by the patient. Cardiac stage is based on the combination of N-terminal pro–B-type natriuretic peptide and high-sensitivity cardiac troponin T. Patients who had a cardiac stage of IIIB at screening were excluded from the trial according to the protocol. The category of cardiac stage IIIA or IIIB includes patients who had a cardiac stage of IIIA at screening but progressed to stage IIIB at cycle 1, day 1. Renal stage is based on the combination of estimated glomerular filtration rate and urinary protein excretion. Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with 0 indicating no symptoms and higher scores indicating increasing disability. High cytogenetic risk was defined by fluorescence in situ hybridization (FISH) testing as a t(4;14) mutation, t(14;16) mutation, or 17p deletion or by karyotype testing as a t(4;14) mutation or 17p deletion. AL denotes immunoglobulin light chain, and NE could not be estimated.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2028631_f2.jpg"><img src="/cms/10.1056/NEJMoa2028631/asset/ca494efe-7239-4761-91c1-451404ae1791/assets/images/large/nejmoa2028631_f2.jpg" height="1958" width="2231" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Kaplan–Meier Estimates of Survival Free from Major Organ Deterioration or Hematologic Progression.</div><div class="notes"><div role="doc-footnote">Shown are the results of the Kaplan–Meier estimates of survival from major organ deterioration or hematologic progression among patients in the intention-to-treat population. Major organ deterioration was defined as end-stage cardiac or renal failure.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Disease Characteristics of the Patients at Baseline (Intention-to-Treat Population).<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Summary of Overall Confirmed Hematologic Responses and Cardiac and Renal Responses at 6 Months.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Most Common Adverse Events during Treatment (Safety Population).<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/385/1" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 385 No. 1</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 01, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2032441" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">D. Schuppan and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 01, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2102605" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">M.B.F. Son and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 01, 2021</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2102968" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Treatment of Multisystem Inflammatory Syndrome in Children</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">A.J. McArdle and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2028631%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2028631&amp;pubId=41290435&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2028631%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2028631&amp;pubId=41290435&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id09121471411599753" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d68a6c257f6224-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d68a6c257f6224-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d68a6c257f6224-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d68a6c257f6224-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d68a6c257f6224-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d68a6c257f6224-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d68a6c257f6224-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d68a6c257f6224-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d68a6c257f6224-SJC"></script>
            
            
            
        
    




<div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div><script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d68a6c257f6224-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d68a6c0a4b6224',t:'MTc0OTUzNDA5Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d68a6c0a4b6224&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script>

        
        
    

<script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2028631?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><iframe name="captureIFrame_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" data-transactionid="cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" id="captureIFrame_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" target="captureIFrame_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" name="capture_screen"><input id="capture_signIn_js_version_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" name="js_version"><input id="capture_signIn_transactionId_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" data-capturefield="undefined" value="cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" type="hidden" class="capture_transactionId_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" name="capture_transactionId"><input id="capture_signIn_form_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" name="form"><input id="capture_signIn_flow_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" name="flow"><input id="capture_signIn_client_id_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" name="client_id"><input id="capture_signIn_redirect_uri_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" name="redirect_uri"><input id="capture_signIn_response_type_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" name="response_type"><input id="capture_signIn_flow_version_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" name="flow_version"><input id="capture_signIn_settings_version_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" name="settings_version"><input id="capture_signIn_locale_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" name="locale"><input id="capture_signIn_recaptcha_version_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_cvk1teec99hd9fqba4w3rirn782ungygkar4drqn" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div><kbx-vjlolseyubcy></kbx-vjlolseyubcy><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div></body></html>